CLINICAL STUDY PROTOCOL
A PHASE 2 DOSE RANGING , RANDOMIZED , DOUBLE BLIND , PLACEBO -
CONTROLLED STUDY EVALUATI NG THE SAFETY , TOLE RABILIT Y ,
PHARMACOKINETICS AND EFFICACY OF EDP -305  IN SUBJECTS WITH PRIMARY 
BILIARY CHOLANGIT IS (PBC)  WI TH OR WI THOUT AN INADEQUATE RESPONSE TO
URSODEOXYCHOLIC ACID (UDCA)
Protocol Number:  EDP [ADDRESS_841164] Number:  2017 -003528 -62
Protocol Version: Version 3.0 (Amendment 2.0, Global US and EU)
Date: Amendment 2.0: 02 Apr 2018
Amendment 1.0 (US only): 12 Dec 2017
Original Protocol: [ADDRESS_841165] 2017
Study Sponsor: Enanta Pharmaceuticals, Inc.
[ADDRESS_841166].
Watertown, MA  [ZIP_CODE]
CONFIDENTIAL 
Information and data in this protocol contain trade secrets and privileged or confidential information, which is the 
property of Enanta Pharmaceuticals, Inc. No person is authorized to make it public without the written permission of 
Enanta Pharmaceuticals, Inc.  
[STUDY_ID_REMOVED]
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page [ADDRESS_841167] INFORMATION 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 3 of 87   
SIGNATURE [CONTACT_200317], and provides 
the necessary assurances that this tria l will be c onducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable U.S. federal regulations and ICH guidelines. 
 
 
Principal Investigator:   
 
[INVESTIGATOR_14586]:  Date:  
 
 
 
 
  
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page [ADDRESS_841168] OF ABBREVIATIONS .................................................................................................... 9  
PROTOCOL SYNOPSIS ........................................................................................................ 11  
1. I NTROD UC TI ON ...................................................................................................... 18  
1.1 OVERVIEW ..........................................................................................................18  
1.2 BACKGROUND ......................................................................................................18  
1.2.1  PBC and Farnesoid X Receptor (FXR) ............................................................[ADDRESS_841169] EXCLUSION CRITERIA .................................................................................39  
4. STUDY DESIGN ........................................................................................................ 41  
4.1 DOSE AND TREA TMENT SCHEDULE ............................................................................41  
4.2 RATIONALE FOR STUDY DESIGN ................................................................................42  
4.2.1  Justification of Design and Control Group .......................................................42  
4.2.2  Justification of EDP- 305 D ose ......................................................................42  
5. STUDY DRUG AND TREATMENT OF SUBJECTS .................................................... 45 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 5 of 875.1 DESCRIPTION OF STUDY DRUG..................................................................................45  
5.2 PACKAGING AND LABELING .....................................................................................45  
5.3 STORAGE ............................................................................................................45  
5.4 ACCOUNTABILITY .................................................................................................45  
5.5 HANDLING AND DISPOSAL .......................................................................................46  
5.6 TREATMEN T ASSIGNMENT AND RANDOMIZATION ...........................................................46  
5.7 STUDY DRUG DOSE AND ADMINISTRATION ..................................................................47  
5.7.1  Dispensing of Study Drug ............................................................................47  
5.7.2  Treatment Com pliance ................................................................................47  
5.8 CONCOMITANT MEDICATIONS ..................................................................................48  
5.8.1  Co-administration of EDP-305 and Ursodiol (ursodeoxycholic acid, UDCA) .............[ADDRESS_841170] AND VISIT SCHEDULE .............................................................. 52  
7.1 STUDY VISITS......................................................................................................52  
7.1.1  Screening ................................................................................................52  
7.1.2  Rescreening .............................................................................................52  
7.1.3  Baseline Visit (Day1) .................................................................................52  
7.1.4  Treatment Period Visits (D ay 3, Weeks 2, 4, 8 and 12 /EOT ) .................................53  
7.1.5  Safety Follow- up Period (End of Study Visit) ....................................................[ADDRESS_841171] WITHDRAWAL /EARLY TERMINATION .............................................................54  
7.2.1  Withdrawal Criteria ...................................................................................54  
7.2.2  Documentation of Withdrawal of Subjects ........................................................55  
7.3 SITE OR STUDY DISCONTINUATION ............................................................................55  
7.3.1  Study Discontinuation .................................................................................55  
7.3.2  Site Termination .......................................................................................55  
7.3.3  Study T ermination Procedures ......................................................................56  
8. STUDY PROCEDURES/EVALUATIONS .................................................................... 57  
8.1 DEMOGRAPHICS AND MEDICAL HISTORY .....................................................................57  
8.2 CLINICAL EVALUATIONS .........................................................................................57  
8.2.1  Vital Sign Measurem ents and ECGs ...............................................................57  
8.2.2  Physical Examination .................................................................................58  
8.2.3  Weight and Body Mass Index (BMI) ...............................................................58  
8.2.4  PBC- 40 Quality of Life Assessment ................................................................58  
8.2.5  Assessm ent of Pruritus ................................................................................58  
8.2.6  Adverse Events .........................................................................................59  
8.3 CLINICAL LABORATORY AND DIAGNOSTIC PROCEDURES ..................................................59  
8.3.1  Safety Laboratory Assessments .....................................................................59  
8.3.2  Pregnancy and Menopausal Laboratory Testing ................................................61  
8.3.3  Noninvasive Evaluations of Fibrosis ...............................................................62  
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 6 of 878.3.4  Biomarkers ..............................................................................................62  
  
8.3.6  Liver Imaging ...........................................................................................63  
8.4 PHARMACOKINETIC SAMPLES ...................................................................................64  
8.4.1  Collection of Pharm acokinetic Sam ples ...........................................................64  
8.4.2  Handling and Bioanalysis of Pharmacokinetic Samples .......................................64  
9. SAFETY MONITORING AND REPORTING .............................................................. 66  
9.1 DEFINITIONS ........................................................................................................66  
9.1.1  Pretreatm ent Events ...................................................................................66  
9.1.2  Adverse Events .........................................................................................66  
9.1.3  Serious Adverse Events (SAEs) ......................................................................66  
9.2 DOCUMENTING AND REPORTING OF ADVERSE EVENTS (INCLUDING SERIOUS ADVERSE 
EVENTS ).............................................................................................................67  
9.2.1  Documenting and Reporting Adverse Events .....................................................67  
9.2.2  Assigning Attribution of Adverse Events ..........................................................68  
9.2.3  Classifying Action Taken with Study Drug ........................................................69  
9.2.4  Classifying Adverse Event Outcom e ................................................................69  
9.2.5  Documenting and Reporting Serious Pretreatment Events and Serious Adverse 
Events ....................................................................................................70  
9.2.6  Documenting and Reporting of Pregnancy .......................................................71  
9.3 FOLLOW -UP OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS .....................................71  
9.4 SPONSOR ’SREVIEW OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS ...........................[ADDRESS_841172] DISPOSITION AND DEMOGRAPHIC DAT A...........................................................75  
11.5 EFFICACY ENDPOINTS ............................................................................................75  
11.5.1  Primary Efficacy Endpoints .........................................................................75  
11.5.2  Secondary Effic acy Endpoints .......................................................................75  
11.6 SAFETY ENDPOINTS ...............................................................................................76  
11.6.1  Adverse Events .........................................................................................76  
11.6.2  Clinical Laboratory Data ............................................................................76  
11.6.3  Electrocardiogram (ECG) Data ....................................................................77  
11.6.4  Vital Signs ...............................................................................................77  
11.6.5  Concomitant Medications ............................................................................77  
11.6.6  Physical Examinations ................................................................................77  
11.7 PHARMACOKINETIC ANALYSES .................................................................................77  
11.8 INTERIM ANALYSES ...............................................................................................78  
12. STUDY ADMINISTRATION ...................................................................................... 79  
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841173] of the Study ........................................................................79  
12.1.2  Ethical Review ..........................................................................................79  
12.1.3  Written Informed Consent ............................................................................79  
12.1.4  Investigator Compliance  .............................................................................80  
12.2 DATA COLLECTION  ...............................................................................................80  
12.3 STUDY MONITORING ..............................................................................................80  
12.4 QUALITY ASSURANCE  ............................................................................................81  
12.5 RECORDS RETENTION .............................................................................................81  
12.6 INFORMATION DISCLOSURE  .....................................................................................81  
12.6.1  Confidentiality ..........................................................................................81  
12.6.2  Publication Policy  .....................................................................................82  
13. REFERENCES  ........................................................................................................... 83  
14. APPENDICES  ............................................................................................................ 86  
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page [ADDRESS_841174] OF FIGURES 
Figure 1: Study Design ........................................................................................................ ......[ADDRESS_841175] OF TABLES 
Table 1:  Safety Pharmacology Studies ...............................................................................22  
  
  
Table 4:  Clinical Studies with EDP-305 .............................................................................26  
  
  
  
 
 
  
Table 10:  EDP 305-005 Part 2 Activity and Treatment Schema ...............................................32  
  
  
  
Table 14:  Laboratory Evaluations .......................................................................................61  
Table 15:  Options for Action Taken with Study Drug ............................................................69  
Table 16:  Classification and Definition of AE Outcomes ........................................................70  
Table 17:  PK Parameters ...................................................................................................[ADDRESS_841176] OF APPENDICES 
Appendix 1:  Schedule of Assessments (SoA)............................................................................86  
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841177] OF ABBREVIATIONS 
ADaM analysis data model 
AE, AR adverse event(s), adverse reaction(s) 
ALT alanine aminotransferase 
APRI AST to platelet ratio index  
AST aspartate aminotransferase 
AUC area under the curve 
BMI body mass index  
BP blood pressure 
CL/F apparent total clearance after oral administration 
Cmax maximum concentration 
eCRF electronic case report form 
CRO contract research organization 
CS, NCS clinically significant, non-clinically significant 
CV cardiovascular 
CYP450, CYP3A4 cytochrome P450, cytochrome P450 3A4 
CYP7A1 cholesterol 7 α-hydrox ylase 
EC ethics committee 
ECG electrocardiogram 
EOS end-of-study 
EOT end-of-treatment 
F oral bioavailability 
FDA Food and Drug Administration 
FIB-4 fibrosis 4 index  
FXR farnesoid X receptor 
GCP, GM P, GLP good clinical practice, good manufacturing practice, good laboratory practice 
HBV hepatitis B virus 
HCV hepatitis C virus 
HDL-C high density lipoprotein cholesterol 
HDPE high density polyethylene 
hERG  human Ether-à-go-go -related gene 
HIV human immunodeficiency virus 
HR heart rate 
hs-CRP high-sensitivity C-reactive protein 
HV healthy volunteers 
IB investigator’s brochure  
ICF informed consent form 
ICH International Council on Harmonisation 
INR international normalized ratio 
IRB institutional review board 
IU international units 
IUD, IUS intrauterine device, intrauterine system 
IWRS interactive web response system 
MAD multiple ascending dose 
MedDRA medical dictionary for regulatory activities 
NAFL, NAFLD non-alcoholic fatty liver, non-alcoholic fatty liver disease 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 10 of 87  NASH non-alcoholic steatohepatitis 
NCI CTCAE National Cancer Institute, Common Terminology Criteria for Adverse Events 
NFS NAFLD fibrosis score 
NOAEL/NOEL no observed adverse effect level / no observed effect level 
OCA obeticholic acid 
PBC primary biliary cholangitis 
PBC-ANAb PBC-specific antinuclear antibodies 
PD pharmacodynamics 
P-gp P-glycoprotein 
PI [INVESTIGATOR_630472] (non-alcoholic fatty liver disease) 
po oral administration (by [CONTACT_1966], per os) 
PT/PTT prothrombin time / partial thromboplastin time 
QD once daily 
SAD single ascending dose 
SAE serious adverse event(s) 
SAP statistical analysis plan 
SHP small heterodimer partner 
SOC system organ class 
S[LOCATION_003]R suspected, unex pected, serious adverse reaction 
t1/2 plasma half-life 
TB total bilirubin 
TEAE treatment emergent adverse event(s) 
Tmax time to maximum concentration 
UDCA ursodeox ycholic acid 
ULN upper limit of normal 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 11 of 87  PROTOCOL SYNOPSIS  
Sponsor:  Enanta Pharmaceuticals, Inc. 
Name [CONTACT_791]:  EDP-305 
Study Title:  A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study 
Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP -305 in Subjects with 
Primary Biliary Cholangit is (P BC) with or wit hout an Inadequate Response to Ursodeoxycholic 
Acid (UDCA)  
Protocol Number:  EDP 305-201  
Phase of Development: 2 
Study Centers:  The study w ill be c onducted at approximately 65 sites located in both the US 
as well as international locations. 
Number of Subjects Planned: Approximately [ADDRESS_841178], Dosage, and Mode of Administration:  EDP-305 w ill be s upplied as 
1mg and 2.5mg tablets for oral administration; doses administered will be 1 mg, 2.5 mg, or 
placebo taken once daily (QD) for 12 weeks.  
Duration of Treatment:  12 weeks.  
Objectives: 
Primary Objective: 
x To evaluate the effect of EDP-305 on alkaline phosphatase (ALP) levels.  
Secondary Objective:  
x To evaluate the safety and tolerabilit y of EDP - [ADDRESS_841179] of EDP-305 on b ilirubin levels 
x To evaluate the effects of EDP-305 on other markers of liver function 
x To evaluate the effects of EDP-305 on non-invasive markers of liver fibrosis 
x To evaluate the effects of EDP-305 on inflammatory markers 
x To evaluate the effects of EDP-305 on lipi[INVESTIGATOR_805]  
x To evaluate the effects of EDP-305 on pruritus  
x To evaluate the effects of EDP-305 on Quality of Life (QoL) 
x To evaluate the pharmacokinetics (PK) of EDP-305 and metabolites in plasma  
x To evaluate the pharmacodynamics (PD) of EDP-305 
 
Criteria for Evaluation: 
Primary Endpoint:  
x Proportion of subjects with at least 20% reduction in ALP from pretreatment value or 
normalization of ALP at Week 12  
 
Secondary Endpoints:  
x Frequency of adverse events (AEs), serious AEs, and AEs leading to discontinuation 
through Week 12 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 12 of 87  x Bilirubin (Total, Conjugated, Unconjugated) decline from Baseline at Week 12 
x Change from Baseline in Alanine aminotransferase (ALT) and Aspartate 
aminotransferase (AST), Gamma-Glutamyl transferase (GGT) at Week 12 
x Change from Baseline of noninvasive liver fibrosis markers (Enhan ced Liver Fibrosis 
[ELF] panel, PRO C3, AST to Platelet Ratio Index [APRI] and fibrosis-4 [FIB-4]) at 
Week 12  
x Change from B aseline in fibrinogen, CRP, IL6, IL1 β, TNF -α, TNF -β , alpha2 
macroglobulin and haptoglobin levels at Week 12 
x Change from Baseline in Triglycerides (TG), Total Cholesterol (TC), High Density 
Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL- C) at 
Week 12 
x Change from Baseline in 5D-itch scale and Visual Analog Score (VAS) at Week 12 
x Change from Baseline in PBC-40 Quality of Life (QoL) at Week 12 
x Pharmacokinetic parameters of EDP-305 (and metabolites): C max, Tmax, and AUC last. 
x Pharmacodynamic  parameters of EDP-305: FGF19, C4 and Bile Acid (BA) at W eek 12  
 
Study Design:   
This is a multicenter, double blind, placebo controlled, dose ranging Phase [ADDRESS_841180] of a Screening  Period, Treatment Period and a Follow- up Period as shown in 
the following table.  
 
Study Period Duration  
Screening Up to 4 weeks (28 
Days) 
Treatment 12 weeks 
Follow-up  4 weeks 
Total approximate maximum duration of participation up to 20 weeks 
 
Screening Period:    After reviewing and signing the Informed Consent Form (ICF), subjects w ill 
be screened and must meet all criteria for entry into the study . The Screening Visit must occur 
between Days -28 and -1 (up to 4 weeks). All Screening assessments must occur within the -28 
to -1 window. 
Treatment Period:  Subjects who have met all study criteria w ill report to the site on the morning 
of Day  1. Subjects must have fasted for at least 8 hours prior to dosing. Subjects w ill be 
randomized in a 3:3:1 manner to r eceive one of two doses of EDP-305 or placebo QD. 
Procedures performed are specified in the Schedule of Assessments ( Appendix 1). Predose 
assessments will be c onducted (including laboratory sample collection) before the subject 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841181] udy drug at home . Subjects will 
take study drug once daily for a total of 12 weeks returning to the clinic for efficacy and safety 
assessments on Day  3 and Weeks 2, 4, 8 and 12. On study days when there is a clinic visit, 
subjects will be administered their daily dose in the clinic . Additional PK and PD samples will 
be collected over a period of 8 hours on Day 1 and Week 12 (Day 84/End of Treatment, [ EOT]) 
from subjects at a subset of sites that have the technical capability to collect and process  
intensive (longer duration) PK and PD samples (PK/PD Sub-study).   
Safety Follow -up and Early Termination Visit:  The safety follow-up visit (or End of Study 
[EOS] visit) will occur [ADDRESS_841182] udy drug for all subjects, including those 
who discontinue treatment early (ie, prior to completing 12 weeks of dosing). Final study 
assessments will be completed at that visit.  
Subjects who di scontinue treatment early should return to the clinic as soon as possible 
following the last dose of study drug for an EOT visit. They should then return for the EOS visit 
[ADDRESS_841183] dose of study drug. 
 Study Design: 
 
 
 
Abbreviations: D=Day;  W=Week 
Eligibility Criteria:  
Inclusion Criteria  
Subjects must meet all of the following criteria to be eligible to participate:  
1. An informed consent document must be signed and dated by [CONTACT_423] 
2. Male and female subjects of any ethnic origin between the ages of [ADDRESS_841184] two of the following criteria: 
x History of ALP above ULN for at least 6 months  

Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 14 of 87  x Positive Anti-Mitochondrial Antibodies (AMA) titers (>1/40 on immunofluorescence or M2 
positive by [CONTACT_373722] [ELISA] or positive PBC- specific antinuclear 
antibodies [PBC- ANAb]) 
x Documented liver biopsy result consistent with PBC (with no cirrhosis) 
4. For subjects with no documented liver biopsy performed within [ADDRESS_841185] undergo a 
transient elastography (Fibroscan) showing liver stiffness <14.[ADDRESS_841186] be on a stable dose of UDCA12-20 mg/kg/day for at least 6 months prior to Screening or 
intolerant of UDCA in the opi[INVESTIGATOR_689] (no UDCA for at least 12 weeks prior to 
Screening) 
6. Alkaline Phosphatase (ALP) ≥1.67 × ULN and/or total bilirubin >ULN but <2  × ULN (<2.4 mg/dL) 
7. Subjects must have Screening laboratory values for Hepatitis B surface antigen (HBsAg), anti- HCV 
antibodies and HCV RNA negative, and Human Immunodeficiency Virus (HIV) 1 and 2 antibodies 
(Ab) as seronegative. NOTE: S ubjects previously infected by [CONTACT_63692] C and treated with 
direct acting antivira ls (DAAs) with sustained virologic response (SVR) for at least [ADDRESS_841187] dose of EDP-305.  Effective methods of 
contraception are defined as:  
x a condom for the male partner and at least one of the following for the female participant: 
o Intrauterine device 
o Oral, injectable, implantable, transdermal, or intravaginal hormonal contraceptive 
Note: The above does not apply to female subjects of non-childbearing potential (ie, 
physiologically incapable of becoming pregnant) defined as: 
- has had a complete hysterectomy greater than or equal to 3 months prior to dosing or 
- has had a bilateral oophorectomy (ovariectomy) or 
- has had a bilateral tubal ligation or fallopi[INVESTIGATOR_630473] 
- is postmenopausal (a demonstration of a total cessation of menses for ≥1 year with an FSH 
level of >35 mIU/mL).  
9. All male participants who have not had a vasectomy must use effective contraception from Day -[ADDRESS_841188] one of the following for a female partner: 
x Intrauterine device 
x Oral, injectable, implantable, transdermal, or intravaginal hormonal contraceptive 
x Be of non-childbearing potential 
10. Male subjects must agree to refrain from sperm donation from the date of S creening until [ADDRESS_841189] dose of study drug 
11. Screening body mass index (BMI) of ≥18 kg/m2  
12. Subject must be w illing and able to adhere to the assessments, visit schedule, prohibitions and 
restrictions, as described in this protocol 
Exclusion Criteria  
Subjects who meet any of the following criteria will not be eligible to participate: 
1. Laboratory Screening Results: 
x AST >5 × ULN 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 15 of 87  x ALT >5 × ULN  
x Patients with Gilbert’s syndrome w ill not be allowed due to interpretability of bilirubin levels  
x Total white blood cells (WBC) <3000 cells/mm3 
x Absolute neutrophil count (ANC) <1500 cells/mm3 
x Platelet count <140,000/mm3 
x Prothrombin time (international normalized ratio, INR) >1.2 
x Serum creatinine >2 mg/dL or creatinine clearance <60 mL/min (based on Cockroft-Gault 
Method) 
2. Suspected to have relevant nonalcoholic fatty liver disea se (NAFLD) as based on the judgment 
of the Investigator at Screening 
3. Known history of alpha-1-Antitrypsin deficiency 
4. Use of immunosuppressants known to have an effect on the liver of patients with PBC (eg, 
colchicine, methotrexate, or azathioprine) in the 3 months preceding Screening. 
5. Current use of fibrates, including fenofibrates. NOTE: Subjects who discontinued fibrates for at 
least [ADDRESS_841190] 6 months 
7. Prior use and/or concomitant treatment with obeticholic acid (OCA) 
8. Use of experimental or unapproved drugs within 1 year of Screening 
9. Any other condition(s) that would compromise the safety of the subject or compromise the 
quality of the clinical study, as judged by [CONTACT_079] (PI) 
10. Pregnant or nursing females 
11. Recipi[INVESTIGATOR_630474] a Model for End-Stage Liver Disease (MELD) 
Score ≥15 
12. Co-existing liver or biliary diseases, such as primary sclerosing cholangitis, choledocholithiasis, 
acute or chronic hepatitis, autoimmune hepatitis, alcoholic liver disease, nonalcoholic 
steatohepatitis (NASH), acute infection of bile duct system or gall bladder, history of 
gastrointestinal bleeding (secondary to portal hypertension), cirrhosis, cholangiocarcinoma 
diagnosed or suspected liver cancers 
13. Cirrhosis with or without complications, including history or presence of: spontaneous bacterial 
peritonitis, hepatocellular carcinoma  
14. Hepatorenal syndrome (type I or II) or Screening serum creatinine >2 mg/dL ( 178 μmol/L)  
15. Prior variceal hemorrhage, uncontrolled encephalopathy, Child-Pugh Class A, B and C, 
esophageal varices, or refractory ascites within the previous 6 months of Screening (defined as 
date informed consent signed) 
16. Patients with a history of severe pruritus requiring current or prior systemi c treatment (e.g., with 
BAS or rifampi[INVESTIGATOR_2513]) 
17. Medical conditions that may cause nonhepatic increases in ALP (e.g., Paget's disease)  
18. Any condition possibly affecting drug absorption (eg, gastrectomy <3 years prior to Screening. 
NOTE: Subjects who have undergone gastric surgeries known to not affect drug absorption such 
as gastric band or gastric sleeve w ill be allow ed if they are stable for at least 1 year prior to 
Screening. 
19. History of regular alcohol consumption exceeding 14 drinks/week for females and 
21 drinks/week for males within 6 months of Screening. One drink is defined as 5 ounces 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 16 of 87  (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) 
20. Participation in a clinical trial within 30 days prior to study drug administration 
21. Clinically significant electrocardiogram (ECG) abnormalities or QTcF greater than [ADDRESS_841191] within 3 months or 5 elimination half- lives (whichever is longer) prior to the 
planned intake of study drug 
25. Use of a new statin regimen from Screening and throughout study duration. 
NOTE: Subjects on a stable dose of statins for at least 3 months prior to Screening are allowed. 
No dose modification during the study w ill be allow ed.  
26. Use of immunosuppressants (eg, systemic corticosteroids) for more than [ADDRESS_841192] Withdrawal: 
Subjects may choose to discontinue from the study at any time . Subjects may also be 
discontinued from the study at any time if the subject, Investigator or Sponsor determines that it 
is not in the best interest of the subject to continue participation . Subjects who prematurely 
withdraw from the study for any reason after having been randomized w ill not be repl aced . 
Subjects who prematurely discontinue treatment early and received at least one dose of st udy 
drug should return to the clinic as soon as possible to complete the EOT Visit and for the Safety 
Follow -up Visit [ADDRESS_841193] dose. 
 
Individual subjects who meet the following Stoppi[INVESTIGATOR_1869] w ill be discontinued from further 
dosing and thorough evaluation and follow -up will be performed: 
x If ALT or aspartate aminotransferase (AST) increases to >5 × Baseline. 
x If ALT or AST increase >2 × Baseline AND the increase is accompanied by a 
concomitant total bilirubin (TB) increase >2 × Baseline OR the INR concomitantly 
increases by >0.2 
x If elevations of ALT/AST are accompanied by [CONTACT_630494], anorexia, nausea, vomiting fever, eosinophilia, and/or rash.   
Statistical Methods: 
Detailed statistical analysis will be outlined in the statistical analysis plan (SAP ).  
Analysis Populations  
x Safety Population: All subjects who receive at least one dose of st udy medication. 
Subjects will be included in the treatment gr oup that corresponds to the study 
medication received during the st udy. 
x Efficacy Population: All subjects who receive at least one dose of st udy medication. 
Subjects will be included in the ra ndomized treatment group. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 17 of 87  x Pharmacokinetic Population:  All subjects receiving active study medication and having 
any measurable plasma concentration of study medication at any timepoint.  
Safety Analyses :  Statistical methods for the safety analyses w ill be primarily descriptive in 
nature. No formal statistical comparisons of EDP -305 dose levels w ill be made. Safety data, 
including adverse events (AEs), vital signs,  ECGs, concomitant medications, and laboratory 
values will be summarized separately for each treatment gr oup. Change from Baseline w ill be 
included in summary tables for vital signs, ECG parameters, and laboratory parameters. Shift 
tables will also be generated for safety laboratory parameters by [CONTACT_630495]. All 
laboratory data will be included in the data listings and all test values outside the normal range 
will be flagged.  AEs will be summarized by [CONTACT_630496] 
(MedDRA) system organ class and preferred term by [CONTACT_1570] . 
Efficacy Analyses:   Proportion of subjects with at least 20% reduction in ALP from pretreatment 
value or normalization of ALP at Week [ADDRESS_841194] comparing each of the active treatment groups to placebo, respectively .    
Pharmacokinetic Analyses:    Plasma PK parameters for each dose level w ill be calculated from 
the concentrations of EDP -305 and its major metabolites (as applicable) measured in predose 
and postdose plasma samples . For each EDP- 305 dose level, descriptive statistics (sample size, 
arithmetic means, geometric means, standard deviation, % coefficient of variation, minimum, 
median, and maximum) will be presented. Figu res will be created to display mean and 
individual subject EDP -305 concentration time curves in plasma on both a linear and 
logarithmic scale. The following PK parameters will be calculated as indicated for plasma 
EDP -305 and its major metabolites: AUC 0- t, Cmax, and T max. 
Sample Size Consideration:   The planned sample size is approximately 105 subjects. Group 
sample sizes of 45 in each active arm and 15 in the placebo arm achieve  83.552% power to 
detect a ratio of the group proportions of 40% . The proportion in the smallest active arm is 
assumed to be 0.[ADDRESS_841195] acebo arm is 10% . The test statistic used is the two-sided 
Mantel -Haenszel test. The significance level of the test is 0.05. To account for a 10% 
discontinuation rate, [ADDRESS_841196] 105 who 
complete treatment, bringing the total number of subjects enrolled to 119.  
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 18 of 87  1. INTRODUCTION 
1.1 Overview 
EDP-305 (also known as EPS-2305, EPC-2305 or EP-022305) is a Farnesoid X Receptor (FXR) 
agonist being investigated as a potential treatment for Nonalcoholic Steatohepatitis (NASH) with 
liver fibrosis and Primary Biliary Cholangitis (PBC). This st udy, EDP 305-201, is a randomized, 
double-blind, pl acebo-controlled, Phase 2 st udy designed to assess the safety, tolerab ility, and 
effectiveness of EDP-305 in subjects with PBC with or without an inadequate response to 
ursodeoxycholic acid (UDCA). 
1.2 Background  
1.2.1 PBC and Farnesoid X Receptor (FXR) 
Bile acids play a key role in regulating liver and metabolic homeostasis including regulation of 
lipid and glucose metabolism mediated through two receptor pathways, FXR and TGR5 
(Matsubara, Li, & Gonzalez, 2013 ). FXR is a member of the nuclear hormone receptor 
superfamily and is considered a master regulator of many bile acid activities including feedback 
regulation of bile acid synthesis, gluconeogenesis and glycogenolysis in the liver, and peripheral 
insulin sensitivity in adipose tissue ( McMahan et al., 2013 ). Given the critical role bile acids play 
in liver homeostasis and the role of FXR in regulating bile acid biosynthesis, FXR has become a 
target for therapeutic intervention in numerous liver diseases including NASH and PBC. 
Primary biliary cirrhosis is an important but uncommon autoimmune disease which 
predominantly affects women. Based on well-defined assessment of cases, the incidence and 
prevalence rates for PBC in Europe, North America, Asia, and Australia are reported as ranging 
from 0.33 to 5.8 per 100,000 inhabitants and 1.91 to 40.2 per 100,000 inhabitants, respectively  
(Boonstra, Beuers, & Ponsioen, 2012) . Kim et al estimated that there were 47,000 prevalent 
cases of PBC in the [LOCATION_002] white population and that approximately 3500 new cases are diagnosed each year  (Kim et al., 2000) . PBC disproportionately affects women (10:1 women to 
men ratio) although some r ecent data s uggest an increasing male prevalence (Lleo et al., 2016) . 
The typi[INVESTIGATOR_630475] 40 and 60 years; r ecent data s uggest that young age at 
diagnosis (ie, < 30 years of age) and male gender indicate a poor prognosis (Boonstra et al., 
2012) . Racial and ethnic differences in PBC patients have not been clearly identified. It is a 
globally recognized autoimmune cholestatic liver disease  (Beuers, Trauner, Jansen, & Poupon, 
2015; Hirschfield & Gershwin, 2013; Selmi, Mackay, & Gershwin, 2011; Webb & Hirschfield, 
2017)  with several characteristics, including: cholestasis, serologic reactivity to 
antimitochondrial antibodies (AMA) or specific antinuclear antibody (ANA) reactivity, with 
accompanying histologic evidence of chronic non-s uppurative, granulomatous, lymphocytic 
small bile duct cholangitis. Without treatment, the disease progresses to cirrhosis and, as the liver 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 19 of 87  fails, complications develop including those related to cirrhosis, portal hypertension and 
hepatocellular carcinoma  (Carbone et al., 2013; Huet et al., 2008; Kuiper et al., 2010; Lammers 
et al., 2014; Trivedi et al., 2016) , liver transplantation or death ensue.  
It is believed that a key result of the immunologic injury in PBC is a rise in the endogenous 
hepatocellular bile acids to cytotoxic levels, causing inflammatory damage, an increase in 
hepatocellular enzymes and apoptosis which over time results in hepatic fibrosis and cirrhosis 
(Beuers, 2006) . Disease progression may take decades from diagnosis to the development of the 
clinical events associated with hepatic decompensation. Early on, patients are typi[INVESTIGATOR_630476], and suspi[INVESTIGATOR_1884] a potential PBC diagnosis is raised by [CONTACT_630497]. Currently, 
patients are more likely to be diagnosed at earlier stages of the disease, secondary to the current 
practice guideline that include screening of liver biochemistries during routine physical exams 
(Floreani et al., 2011; Prince, Chetwynd, Craig, Metcalf, & James, 2004).   
Clinically, PBC is monitored by [CONTACT_630498] (ALP) levels. ALP is used universally in the diagnosis of the disease (as noted in both the US and r ecent European 
treatment guidelines  (European Association for the Study of the Liver, 2017; Lindor et al., 2009) . 
However, other liver enzymes including gamma-glutamyltransferase (GGT), alanine 
aminotransferases (ALT) and aspartate aminotransferase (AST) are also used in the clinical 
assessment and care of patients. As the disease progresses and hepatocellular function is 
impaired, bilirubin levels (a direct measurement of hepatic degradation) rise and albumin and 
prothrombin time (assays of hepatic synthesis) are impaired. 
1.2.[ADDRESS_841197] recently, there has been one approved treatment for PBC, ursode oxycholic acid 
(UDCA), which was approved by [CONTACT_34033] 1997. UDCA is effective in more than 50 percent 
of patients, but up to 40 percent of patients do not achieve an adequate reduction in blood 
chemistries (eg, ALP and/or total bilirubin) with UDCA, while 5% to 10% are unable to tolerate 
UDCA. While UDCA therapy has a marked impact on clinical outcomes in PBC, up to 40% of 
UDCA-treated patients have a suboptimal or absent response to UDCA and, as such, are at 
significantly increased risk of an adverse outcome (death, requiring a liver transplant, or other 
clinical complications)  (Carbone et al., 2013; Corpechot et al., 2008; ter Borg, Schalm, Hansen, 
& van Buuren, 2006) . Several studies have shown that UDCA-treated patients with early stage 
disease, who respond biochemically to UDCA treatment, have survival rates comparable with a 
standardized general population (Carbone et al., 2013; Corpechot et al., 2008; ter Borg et al., 
2006) . In 2016, the U.S. Food and Drug Administration granted accelerated approval for the 
FXR agonist Ocaliva® (obeticholic acid, OCA) for the treatment of PBC in combination with 
UDCA in adults with an inadequate response to UDCA, or as a single therapy in adults unable to 
tolerate UDCA (U.S. Food and Drug Administration, 2016) . 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841198] in various 
diseases, including cholestatic and autoimmune liver diseases, alcoholic liver disease, fatty liver, gallstone formation, portal hypertension, and hepatocellular carcinoma. It has been recently 
reported that EDP-305 potently suppresses liver injury and fibrosis in mouse models of b iliary 
and metabolic liver disease (An et al., 2017) . Furthermore, in the MCD diet mouse model of 
steatohepatitis and perisinusoidal fibrosis, EDP-[ADDRESS_841199] 
that EDP-305 has the potential to satisfy this unmet medical need. 
1.3 Nonclinical Studies 
1.3.1 Mechanism of Action and Pharmacology 
A summary of pharmacology studies is presented below. Additional details for each study as 
well as details on additional studies can be found in the Inv estigator’s Brochure (IB) . As noted 
for each st udy, the natural agonist of FXR, chenodeoxycholic acid (CDCA) and/or it’s close 
synthetic analog obeticholic acid (OCA), were used as controls. OCA has recently been approved for the treatment of PBC. 
[IP_ADDRESS]  Mechanism of Action 
EDP-[ADDRESS_841200] which, as discussed above, plays an essential role in the feedback 
regulation of bile acid biosynthesis. The efficacy and potency of EDP-305 was demonstrated in 
several in vitro  assays.   
x In FXR Chinese Hamster Ovary (CHO) cell reporter assays and full-length FXR Human 
Embryonic Kidney 293 (HEK 293) cell reporter assays, EDP-305 and its major 
metabolites were potent stimulators of FXR activity. 
x In human Huh7.5 hepatocyte cells, EDP-305 effected a dose-dependent increase in SHP 
gene expression and decrease in CYP7A1 mRNA expression. 
x In reporter gene assays measuring activation of 25 different nuclear receptors, only FXR 
was activated following incubation with EDP-305. 
[IP_ADDRESS]  In Vitro Pharmacology 
The ability of EDP - 305 to regulate over 30 key genes involved in bile acid and lipid metabolism, 
inflammation, fibrosis, and glucose metabolism was evaluated using in vitro  systems. OCA was 
used as a comparator/control in all cases. The results, which are described in the IB, 
demonstrated that EDP-305 affected the expression of 38 genes important in bile acid (5 genes) 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 21 of 87  and lipid (9 genes) metabolism, inflammation (10 genes), fibrosis (8 genes) and glucose 
metabolism (6 genes).   
[IP_ADDRESS]  In Vivo Pharmacology 
The efficacy of EDP- 305 was demonstrated in animal models of disease: 
x The regulation of FXR downstream genes critical for bile acid metabolism was assessed 
in C57BL/6 mice treated with EDP-305 or OCA orally for five days. EDP-305 induced a 
dose-dependent increase in FGF15 and SHP gene expression in the ileum, and dose-
dependent increases in SHP and BSEP mRNA and decreases in CYP7A1 mRNA in the 
liver. In all cases, EDP-305 was more active than OCA. 
x STAM mice develop NASH, fibrosis and ultimately hepatocellular carcinoma, in a 
manner replicating the pathological progression seen in the human disease. Treatment of 
STAM mice with EDP-305 for 4 weeks resulted in a significant reduction in non-fasted 
blood glucose levels, significant improvement in the NAFLD activity score (NAS), and 
significant reductions in key genes associated with fibrosis (ie, smooth muscle actin), and 
lipogenesis (sterol regulatory element binding protein 1c). In all cases, EDP-305 was 
more active than OCA. 
x The effects of preventative and therapeutic treatment with EDP-305 and OCA on hepatic 
lipi[INVESTIGATOR_630477] a hamster model of dyslipi[INVESTIGATOR_035]. In this study, treatment began 
concurrently with the start of a 4-week high fat/high cholesterol diet (preventative model) 
or two weeks later (therapeutic model). EDP-305 and OCA stimulated significant 
reductions in hepatic lipid levels in both the therapeutic and preventative treatment 
protocols. Additionally, both EDP-305 and OCA showed a moderate reduction in 
HOMA-IR and plasma insulin levels in the therapeutic model, suggesting the potential 
for improvement in insulin sensitivity. 
x Mdr2-/- mice develop progressive biliary-type (periportal) fibrosis resembling that 
observed in PSC, PBC, CFLD and congenital b iliary cirrhosis  ( Ikenaga et al., 2015 ). In 
Mdr2-/- mice with pre-established fibrosis, administration of EDP-305 (10 or 30 mg) 
resulted in significant decreases in serum ALT and AST levels compared to vehicle 
controls. Mice receiving OCA (30 mg/kg) had a significant decrease in AST but not ALT 
levels. Histologically, treatment with EDP-305 resulted in a marked attenuation of 
fibrosis compared to placebo control mice with a 39% reduction in hepatic collagen 
content. Treatment with OCA at 30 mg/kg did not result in a histological improvement in 
fibrosis, and had no significant impact on hepatic collagen levels. Thus, treatment with 
EDP-305 potently improved pre-established liver injury and hepatic fibrosis in Mdr2-/- 
mice outperforming OCA in all parameters measured. 
1.3.2 Safety Pharmacology  
EDP-305 was tested in a battery of safety and secondary pharmacology studies. The results of 
the safety pharmacology tests are shown below in Table 1 . A detailed description of the studies 
and results can be found in the IB. 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 22 of 87Table 1: Safety Pharmacology Studies  
System / Stud yTestSystem
(route)Dose or 
ConcentrationResults
CV/ Radioligand
hERG  Binding AssayHEK293 Cells
(in vitro )3and 10μM EDP-305 was inactive in this assay.
CV / hERG Patch
Clam p Assa yHEK293 Cells 
(in vitro )0.3, 1, 3, 10
μMIC50was estimated to be >1 μM due to disruption of the 
giga-ohm seal required for successful recordings at 3 and 
CV / Pharmacology&
TK StudyCynomolgus 
monkeys (oral)100, 200, 400
mg/kgNOEL was 400 mg/kg; EDP-[ADDRESS_841201] survival, 
body temperature, blood pressure, heart rate or ECG .
CNS / Safety
Pharmacology StudyCrl:CD1® (ICR) 
mice (oral)25, 50, 100NOEL was 100 mg/kg; EDP-305 did not elicit any 
adverse effects as assessed via FOB evaluations
Respi[INVESTIGATOR_696] / Safety
Pharmacology StudyCrl:CD1® (ICR) 
mice (oral)25, 50, 100NOEL was 100 mg/kg; EDP-[ADDRESS_841202] respi[INVESTIGATOR_862], tidal volume or minute volume
Abbreviations:  Human embryonic kidney (HEK), Cardiovascular (CV), Toxicokinetics (TK), No-observed-effect-level (NOEL), 
Central nervous system (CNS), Functional observation battery (FOB) , Electrocardiogram (ECG)
1.3.3 Pharmacokinetics 
A series of nonclinical studies were conducted to assess the pharmacokinetics and metabolism of 
EDP-305.
[IP_ADDRESS] Absorption 
The absorption of a single oral dose of EDP-305 was evaluated in CD-1 mice, Sprague-Dawley 
rats, Beagle dogs, and Cynomolgus monkeys. The studies showed that EDP-305 was well 
absorbed with a calculated oral bioavailability of 9.0% in monkeys, 26.0% in mice, 29.2% in 
dogs, and 33.3% in rats. An evaluation of membrane permeab ility to EDP - 305 was performed 
using Caco-2 cells and showed a high in vitro  permeability of 8.7 x 10-6 to 10.8 x 10-6 cm/sec at 
concentrations tested from 0.[ADDRESS_841203] a good oral absorption in humans. 
[IP_ADDRESS] Distribution 
Drug concentrations in the plasma, liver, and kidney were measured following 5-day oral 
administrations of EDP-305 to mice at 25, 50 or 100 mg/kg. Results showed that EDP-305
preferentially penetrated into the liver, which is the target organ of NASH and PBC. The liver-
to-plasma exposure ratio ranged from 6.0 – 13.8. 
As determined by [CONTACT_630499], plasma protein binding of EDP - 305 (1 μg/mL) was 
>99.9% in mouse, rat, dog, monkey, and human. The in vitro  partitioning of EDP-305 between 
plasma and formed elements (erythrocytes, leukocytes, and platelets) of whole blood was also 
evaluated. The blood-to-plasma concentration ratios ranged from 0.46 –0.57 in human, 
indicating that EDP-305 had a preferential distribution into the plasma compartment. The blood 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 23 of 87to plasma partition ratio was independent of the concentrations evaluated (0.1, 0.5, 1 and 2 
μg/mL). 
[IP_ADDRESS] Metabolism 
The metabolic stability of EDP - [ADDRESS_841204] intrinsic 
clearance (Cl int) of 41.0 μL/min/kg in monkey liver microsomes, and had the lowest intrinsic 
clearance of 6.5 μL/min/kg and 6.9 μL/min/kg in rat and human liver microsomes, respectively.
 The human 
metabolites observed in in vitro  liver microsome incubations were also formed in mouse and/or 
monkey, the primary species for general toxicology studies. Thus, no metabolites unique to 
humans have been observed to date. 
[IP_ADDRESS] Drug Interactions 
Based on preclinical evaluation, EDP-[ADDRESS_841205] that there is potential for EDP-305 to inhibit organic anion-
transporting polypeptide (OATP)1B1 and OATP1B3. EDP-305 has low potential to inhibit 
BSEP, multidrug resistance-associated protein 2 (MRP2), P-glycoprotein (P-gP), and breast 
cancer resistance protein (BCRP) transporters. EDP- 305 is unlikely to be a BCRP substrate but 
has potential to be a P-gP substrate. 
1.3.4 Toxicology 
The nonclinical safety assessment program evaluated the potential toxicity of EDP-305 in pi[INVESTIGATOR_630478] (mouse and monkey) and in non-pi[INVESTIGATOR_36491] (rat, mouse, and monkey). In all 
studies, the vehicle was 0.5% (w/v) methylcellulose in water (ultrapure, reverse osmosis or 
NANOpure). The mouse was chosen as the rodent species for the definitive studies based on the 
presence of a gallbladder in this species versus the rat. The monkey was chosen as the non-
rodent species owing to the similar metabolic profiles between monkey and human. Results of 
key studies are presented below while details of all studies can be found in the IB. 
[IP_ADDRESS] Repeat-dose Toxicology Studies 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page [ADDRESS_841206] been conducted and/or are ongoing with EDP-[ADDRESS_841207]-in-Human (FIH) study in healthy volunteers (HV) and in subjects with presumptive 
NAFLD (PN), a hepatic impairment study, two drug: drug interaction (DDI) studies, and a 
bioavailability (BA) study ( Table 4 ).
Table 4: Clinical Studies with EDP-305
Stud y I D Phase 
/ TypePopulation
Planned/Actual 
(N)Title
EDP 305-001 1 / FIH HV & PN / 
N=42/50(HV), 
N=48/96(PN)A Randomized, Double-Blind, Placebo-Controlled, First-In-
Human Study of Orally Administered EDP -305 to Evaluate the 
Safety, Tolerability, and Pharmacokinetics of Single Ascending 
Doses (SAD), Multiple Ascending Doses (MAD) and the Effect of 
Food on EDP -305 P harmacokinetics in Healthy Subjects, and of 
Multiple Ascending Doses (MAD) in Subjects with Presumptive 
NAFLD
EDP 305-003 1 / HI HV, mild & 
moderate HI / 
N=30/29 A Phase 1, Open-Label, Parallel G roup, Single Dose Study to 
Evaluate the Pharmacokinetics, S afety and Tolerability of EDP -
305 in Subjects with Varying Degrees of Hepatic Function
EDP 305-004 1 / 
DDIHV / N=24/[ADDRESS_841208] of Concomitant 
Administration of EDP -305 on t he Pharmacokinetics and Safety of 
Midazolam, Caffeine, and Rosuvastatin in Healthy Human 
V olunteers
EDP 305-005 1 / 
DDIHV / N=48/48 A Non-Randomized, Open-Label, Two-Part, Drug-Drug 
Interaction Study to Evaluate the Effects of Itraconazole and 
Rifampin on the Pharmacokinetics and Safety of EDP-305 in 
Healthy V olunteers
EDP 305-006 1 / BA HV / N=18/[ADDRESS_841209], 3-Period 
Crossover, 6 -Sequence Bioavailability Study Comparing the 
Pharmacokinetics of EDP -305 Suspension (re ference) to Tablet 
(test) in Healthy Human V olunteers under Fed and Fasted 
Conditions
Abbreviations:  Pop. (study population); FIH (first-in-human); HV (healthy volunteer(s)); PN (presumptive 
NAFLD); HI (hepatic impairment); DDI (drug:drug interaction); BA (bioavailability)
1.4.[ADDRESS_841210]-In-Human Study of Orally Administered EDP-
305 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), 
Multiple Ascending Doses (MAD) and the Effect of Food on EDP-305 Pharmacokinetics in Healthy 
Subjects, and of Multiple Ascending Doses (MAD) in Subjects with Presumptive NAFLD 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 27 of 87  A Phase 1 FIH study (EDP 305-001) to evaluate the safety, tolerab ilit y, and pharmacokinetics of 
EDP-305 in healthy volunteers (HV) and subjects with presumptive NAFLD (PN) was 
conducted.  The study included 2 phases:  a Single Ascending Dose (SAD) phase enro lling 
healthy adult subjects, including a “fasted” versus “fed” two -part cohort to assess food effect 
(SAD/FE), and a Multiple Ascending Dose (MAD) phase enrolling healthy adult subjects into 3 cohorts, and subjects with PN into 3 cohorts.  A total of 42 HV were planned to be enrolled into 
6 SAD cohorts at doses of 1, 5, 10, 20, and 40 mg EDP-305/pl acebo and a total of 48 subjects 
were planned to be enrolled into 3 MAD-HV cohorts (5, 10, 20 mg EDP-305/placebo) and 3 MAD-PN cohorts (5, 10, 20 mg EDP-305/placebo).  The study was amended to add a 80 mg 
cohort in the SAD phase, and 6 MAD cohorts (3 HV and 3 PN) assessing [ADDRESS_841211] population.  In all cohorts except SAD/FE, 8 
subjects were enrolled at a randomization ratio of 3:1 (6 r eceiving EDP- 305 and 2 receiving 
placebo (PBO)).  Ten subjects were enrolled in the SAD/FE cohort and randomized 4:1, EDP-[ADDRESS_841212] acebo, 
and were included in the safety analyses: 50 healthy subjects in the SAD phase, and 48 healthy 
subjects and 48 subjects with presumptive NAFLD in the MAD phase. 
EDP-305 was generally well tolerated at single doses up to 80 mg and at multiple doses up to 20 
mg for 14 days. TEAEs occurring in ≥ 2 EDP -305 treated subjects in MAD were: headache and 
pruritus in HV, and constipation and pruritus in PN.  No SAEs or Grade 4 AEs were reported.  
Drug related pruritus was reported after multiple dosing at the higher doses of EDP -305 10 mg 
(n=2) and 20 mg (n=7), and PBO (n=1), with 1 discontinuation at 20 mg in HV (moderate).  
Majority of drug related pruritus were mild to moderate (except one subject with severe). No 
pruritus was observed at lower doses (below 10 mg). No clinically significant laboratories were 
reported except one transient Grade 2 ALT/AST elevation in one subject (MAD-HV-20 mg) that 
led to drug discontinuation. Total, LDL-, HDL- cholesterol and triglycerides did not differ 
between EDP-[ADDRESS_841213] acebo in either healthy or PN subjects at any dose, except at 20 mg in 
PN for cholesterol and HDL. 
A dose proportional increase in exposure was observed following single and multiple doses of 
EDP-305.  Pharmacokinetic (PK) profiles following single doses of EDP-305, indicated linear, 
one-compartment PK, with monophasic decline.  Half-life was similar following single doses 
with a mean ranging from 11 to 16 hours.  A high fat meal increased EDP -305 exposure by 
[CONTACT_3450] 200%.  Half-life ranged from 10-23 hours following multiple doses of EDP-305.    
There was more drug accumulation (~3-fold) observed following 20 mg dose compared to lower 
doses. Similar exposures were observed in both HV and PN subjects.  The metabolite (EP -
022571, EP-022572 and EP-022679) levels were generally low (<5% of parent drug), following 
single and multiple doses of EDP-305.  EDP-305 and metabolite levels in the urine were low and 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 31 of 87  
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 33 of 87   
  
  
  
  
  
  
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 34 of 87  
   
  
  
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page [ADDRESS_841214] been estimated based on results from the 
repeat dose toxicity studies and safety data from the Phase 1 study (EDP 305-001) conducted in 
healthy volunteers and subjects with presumptive NAFLD (PN). 
Safety data from EDP 305-001:   
xEDP-305 was generally well tolerated at single doses up to 80 mg and at multiple doses 
up to 20 mg for 14 days.  
xTEAEs occurring in ≥ 2 EDP -305 treated subjects were: headache and pruritus in HV, 
and constipation and pruritus in PN.  
xNo clinically significant laboratories were reported except one transient Grade 2 
ALT/AST elevation in n=1 (MAD-HV-20mg) that led to drug discontinuation.  
xNo effects on lipi[INVESTIGATOR_630479] 14 days except for cholesterol and HDL at 20 mg 
in PN. 
xMajority of drug related pruritus were mild to moderate (except n=1) and reported after 
multiple dosing at the higher doses of EDP-305 10 mg (n=2/12) and 20 mg (n=7/12), and 
PBO (n=1/24), with 1 drug discontinuation at 20 mg in HV. No pruritus was observed at 
any multiple doses below 10mg.  
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841215] of EDP -305 on ALP levels. 
2.1.2 Secondary Objective s 
The secondary objectives of the study are as follows: 
x To evaluate the safety and tolerabilit y of EDP - [ADDRESS_841216] of EDP-305 on b ilirubin levels 
x To evaluate the effects of EDP-305 on other markers of liver function 
x To evaluate the effects of EDP-305 on non-invasive markers of liver fibrosis 
x To evaluate the effects of EDP-305 on inflammatory markers 
x To evaluate the effects of EDP-305 on lipi[INVESTIGATOR_805]  
x To evaluate the effects of EDP-305 on pruritus  
x To evaluate the effects of EDP-305 on Quality of Life (QoL) 
x To evaluate the PK of EDP-[ADDRESS_841217] 20% reduction in 
ALP from pretreatment values or normalization of ALP at Week 12. 
2.2.2 Secondary Endpoints 
The secondary endpoints are as follows: 
x Frequency of adverse events (AEs), serious AEs, and AEs leading to discontinuation 
through Week 12 
x Bilirubin (Total, Conjugated, Unconjugated) decline from Baseline at Week 12 
x Change from Baseline in Alanine aminotransferase (ALT) and Aspartate 
aminotransferase (AST), Gamma-Glutamyl transferase (GGT) at Week 12 
x Change from Baseline of noninvasive liver fibrosis markers (Enhanced Liver Fibrosis 
[ELF] panel, PRO C3, AST to Platelet Ratio Index [APRI] and fibrosis-4 [FIB-4]) at 
Week 12  
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 37 of 87  x Change from B aseline in fibrinogen, CRP, IL6, IL1 β, TNF -α, TNF -β , alpha2 
macroglobulin and haptoglobin levels at Week 12 
x Change from Baseline in Triglycerides (TG), Total Cholesterol (TC), High Density 
Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C) at 
Week 12 
x Change from Baseline in 5D-itch scale and Visual Analog Score (VAS) at Week 12 
x Change from Baseline in PBC-40 Quality of Life (QoL) at Week 12 
x Pharmacokinetic parameters of EDP-305 (and metabolites): C max, Tmax, and AUC last 
x Pharmacodynamic parameters of EDP-305: FGF19, C4, and Bile Acid (BA) at Week 12 
 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841218] meet all of the following criteria to be enrolled into this study: 
1. An informed consent document must be signed and dated by [CONTACT_423] 
2. Male and female subjects of any ethnic origin between the ages of [ADDRESS_841219] two of the following criteria: 
x History of ALP above ULN for at least 6 months  
x Positive Anti-Mitochondrial Antibodies (AMA) titers (>1/40 on immunofluorescence or 
M2 positive by [CONTACT_373722] [ELISA] or positive PBC-specific 
antinuclear antibodies [PBC- ANAb]) 
x Documented liver biopsy result consistent with PBC (with no cirrhosis) 
4. For subjects with no documented liver biopsy performed within [ADDRESS_841220] 
undergo a transient elastography (Fibroscan) showing liver stiffness <14.[ADDRESS_841221] be on a stable dose of UDCA 12-20 mg/kg/day for at least 6 months prior to Screening 
or intolerant of UDCA in the opi[INVESTIGATOR_689] (no UDCA for at least 12 weeks 
prior to Screening) 
6. Alkaline Phosphatase (ALP) ≥1.67 × ULN and/or total bilirubin >ULN but <2  × ULN 
(<2.4 mg/dL) 
7. Subjects must have Screening laboratory values for Hepatitis B surface antigen (HBsAg), 
anti-HCV antibodies and HCV RNA negative, and Human Immunodeficiency Virus (HIV) 1 
and 2 antibodies (Ab) as seronegative. NOTE: Subjects previously infected by [CONTACT_630500] C and treated with direct acting antivirals (DAAs) with sustained virologic res ponse 
(SVR) for at least [ADDRESS_841222] dose of EDP- 305.  
Effective methods of contr aception are defined as:  
x a condom for the male partner and at least one of the following for the female participant: 
o Intrauterine device 
o Oral, injectable, implantable, transdermal, or intravaginal hormonal contraceptive 
Note: The above does not apply to female subjects of non-childbearing potential (ie, physiologically incapable of becoming pregnant) defined as: 
- has had a complete hysterectomy greater than or equal to 3 months prior to dosing or 
- has had a bilateral oophorectomy (ovariectomy) or 
- has had a bilateral tubal ligation or fallopi[INVESTIGATOR_630480] 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 39 of 87  - is postmenopausal (a demonstration of a total cessation of menses for ≥1 year with an 
FSH level of >35 mIU/mL).  
9. All male participants who have not had a vasectomy must use effective contraception from 
Day -[ADDRESS_841223] one of the following for a 
female partner: 
x Intrauterine device 
x Oral, injectable, implantable, transdermal, or intravaginal hormonal contraceptive 
x Be of non-childbearing potential 
10. Male subjects must agree to refrain from sperm donation from the date of Screening until 
[ADDRESS_841224] dose of study drug 
11. Screening body mass index (BMI) of ≥18 kg/m2  
12. Subject must be willing and able to adhere to the assessments, visit schedule, prohibit ions and restrictions, as described in this protocol 
3.[ADDRESS_841225] udy: 
1. Laboratory Screening Results: 
x AST >5 × ULN 
x ALT >5 × ULN  
x Patients with Gilbert’s syndrome w ill not be allowed  due to interpretability of bilirubin 
levels 
x Total white blood cells (W BC) < 3000 cells/mm3 
x Absolute neutrophil count (ANC) <1500 cells/mm3 
x Platelet count <140,000/mm3 
x Prothrombin time (international normalized ratio, INR) >1.2 
x Serum creatinine >2 mg/dL or clearance creatinine <60 mL/min (based on Cockroft-
Gault Method) 
2. Suspected to have relevant nonalcoholic fatty liver disease (NAFLD) as based on the 
judgment of the Investigator at Screening 
3. Known history of alpha-1-Antitrypsin deficiency 
4. Use of immunosuppressants known to have an effect on the liver of patients with PBC (eg, colchicine, methotrexate, or azathioprine) in the 3 months preceding Screening. 
5. Current use of fibrates, including fenofibrates. NOTE: Subjects who discontinued fibrates for at least [ADDRESS_841226] 6 months 
7. Prior use and/or concomitant treatment with OCA 
8. Use of experimental or unapproved drugs within 1 year of Screening 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 40 of 87  9. Any other condition(s) that would compromise the safety of the subject or compromise the 
quality of the clinical study, as judged by [CONTACT_079] (PI) 
10. Pregnant or nursing females 
11. Recipi[INVESTIGATOR_630481] a Model for End-Stage Liver Disease (MELD) 
Score ≥15 
12. Co-existing liver or biliary diseases, such as primary sc lerosing cholangitis , 
choledocholithiasis, acute or chronic hepatitis, autoimmune hepatitis, alcoholic liver disease, 
nonalcoholic steatohepatitis (NASH), acute infection of bile duct system or gall bladder, 
history of gastrointestinal bleeding (secondary to portal hypertension), cirrhosis, 
cholangiocarcinoma diagnosed or suspected liver cancers 
13. Cirrhosis with or without complications, including history or presence of: spontaneous 
bacterial peritonitis, hepatocellular carcinoma 
14. Hepatorenal syndrome (type I or II) or Screening serum creatinine >2 mg/dL (178 μmol/L)  
15. Prior variceal hemorrhage, uncontrolled encephalopathy, Child-P ugh Class A, B and C, 
esophageal varices, or refractory ascites within the previous 6 months of Screening (defined 
as date informed consent signed) 
16. Patients with a history of severe pruritus requiring current or prior systemic treatment (e.g., 
with BAS or rifampi[INVESTIGATOR_2513]) 
17. Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease)  
18. Any condition possibly affecting drug absorption (eg, gastrectomy <3 years prior to Screening). NOTE: Subjects who have undergone gastric surgeries known to not affect drug 
absorption such as gastric band or gastric sleeve  will be allowed if they are stable for at least 
1 year prior to Screening. 
19. History of regular alcohol consumption ex ceeding 14 drinks/week for females and 
21 drinks/week for males within 6 months of Screening. One drink is defined as 5 ounces 
(150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) 
20. Participation in a clinical trial within 30 days prior to study drug administration 
21. Clinically significant electrocardiogram (ECG) abnormalities or QTcF greater than [ADDRESS_841227] within 3 months or 5 elimination half-lives (whichever is longer) prior to 
the planned intake of study drug  
25. Use of a new statin regimen from Screening and throughout study duration. 
NOTE: Subjects on a stable dose of statins for at least 3 months prior to Screening are 
allowed. No dose modification during the study w ill be allowed.  
26. Use of immunosuppressants (eg, systemic corticosteroids) for more than 2 consecutive weeks 
in duration within 1 year prior to Screening. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841228] udy assessing 
the safety, tolerability, pharmacokinetics, and efficacy of two doses of EDP-305 in subjects with 
PBC with or without an inadequate response to UDCA.  
The study is composed of 3 phases or periods:  
x Screening period which includes the Screening Visit and may occur over a time period of 
[ADDRESS_841229] dose of study drug on Day 1 and concludes 
with the End of Treatment (EOT) Visit on Day 84 (Week12) 
x Safety Follow-up period which includes the End of Study (EOS) Visit on Day 112. 
4.1 Dose and Treatment Schedule  
Subjects will be ra ndomized in a 3:3:[ADDRESS_841230] udy drug for a total of 12 weeks. An 
overview of the study design is shown in Figure 1. Study visits and assessments are detailed in 
the Schedule of Assessment (SoA) in Appendix 1. 
Figure 1: Study Design 
 
 
Abbreviations: D=Day; W=Week  

Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 42 of 87  4.2 Rationale for Study Design  
This proposed trial w ill evaluate EDP - 305 in patients with PBC who w ill be ra ndomized to one 
of three treatment groups: (1) 1 mg EDP-305, (2) 2.5 mg EDP-305, or (3) pl acebo in a 3:3:1 
ratio. 
4.2.1 Justification of Design and Control Group 
Until recently, ursode oxycholic acid (UDCA) has been the only approved treatment for PBC, 
which was approved by [CONTACT_34033] 1997.  While UDCA therapy has a marked impact on clinical 
outcomes in PBC, up to 40% of UDCA-treated patients have a suboptimal or absent response to 
UDCA and, as such, are at significantly increased risk of an adverse outcome (death, requiring a liver transplant, or other clinical complications)  (Carbone et al., 2013 ; Corpechot et al., 2008 ; 
ter Borg et al., 2006 ) (U.S. Department of HHS Organ Procurement and Transplantation 
Network.) ( https://optn.transplant.hrsa.gov , Sept 5, 2016). In May 2016, the U.S. Food and Drug 
Administration granted accelerated approval for the FXR a gonist Ocaliva
® (obeticholic acid, 
OCA) for the treatment of PBC in combination with UDCA in adults with an inadequate 
response to UDCA, or as a single therapy in adults unable to tolerate UDCA (U.S. Food and 
Drug Administration, 2016). The confirmatory trials are ongoing.  
This Phase [ADDRESS_841231] therapi[INVESTIGATOR_630482]. The use of placebo is implemented to maintain the study blind and scientific validity of the trial. Some patients cannot tolerate UDCA; their 
standard of care does not include UDCA. Patients taking drugs that might have effects in PBC or 
recently c onditionally approved (i.e., OCA) are being excluded from the trial to ensure that the 
trial provides the clearest comparison of the effects of EDP -[ADDRESS_841232] acebo. 
4.2.2 Justification of EDP-305 Dose 
This phase 2 trial has been designed to assess the efficacy, safety and tolerab ilit y of 2 doses (1 
mg, and 2.5 mg) of EDP-[ADDRESS_841233] range of single and multiple doses: from 1 to 80 mg in 
the SAD part, and from 0.5 to 20 mg in the MAD part, and administered as an oral suspension.  
The safety and tolerabilit y of EDP - 305 has been established not only in healthy subjects but also 
in subjects with presumptive NAFLD at doses up to 80 mg single dose and up to 20 mg once 
daily for 14 consecutive days. 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 43 of 87As demonstrated in study EDP 305-001, EDP-305 was generally well tolerated at single doses up 
to 80 mg and at multiple doses up to 20 mg for 14 days. No SAEs or Grade 4 AEs were reported.  No clinically significant laboratories were reported except one transient Grade 2 ALT/AST 
elevation in n=1 (MAD-HV-20mg) that led to drug discontinuation. Drug related pruritus was 
reported after multiple dosing at the higher doses of EDP-305 10 mg (n=2) and 20 mg (n=7), and PBO (n=1), with [ADDRESS_841234] udy 006, ( Section [IP_ADDRESS]), 
EDP-305 doses of 1 and 2.5 mg once daily using the tablet formulation are selected for this 
study. The exposures associated with this dose range are expected to result in clinically 
meaningful changes in C4 and other relevant markers of FXR activity (FGF-19), while 
minimizing the incidence of potential adverse events (i.e. pruritus). 
Doses of 1 and 2.5 mg using the tablet formulation in the fasted state 
(comparable to approximately 2.5 and 5 mg using the suspension formulation in the fasted state) 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 44 of 87  are expected to provide exposures associated with clinically meaningful changes in C4 and FGF-
19, while minimizing the incidence of potential adverse events (i.e. pruritus). 
In summary, based on data from studies 001, 004, and 006, doses of 1 and 2.5 mg are expected to 
provide: 
x A safe and tolerable regimen with lowest chance to induce pruritus 
x Plasma exposures representing linear, time-independent PK and correlated with desirable 
dose dependent changes in PD markers suitable for a once daily dosing 
x Maximal decreases in C4 ranging from approximately 67% to 85% at steady state and 
associated increases in FGF-19 ranging from approximately 1000% to 1700% at steady 
state.  Given the similarity in the MOA between EDP-305 and OCA, the expected 
changes in C4/FGF-19 over the selected dose range for EDP-305 in phase 2 studies, are 
expected to be associated with relevant downstream pharmacological effects clinically 
relevant changes in liver markers. 
 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page [ADDRESS_841235] acebo tablets should be stored under refrigerated 
conditions (2°C – 8°C) at all times. 
Additional information will be provided in the Pharmacy Manual. 
5.[ADDRESS_841236] acebo tablets in bottles will be shipped to the clinical site 
and stored under refrigerated conditions (2°C –8°C).
5.[ADDRESS_841237] or designated study staff w ill maintain 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 46 of 87  adequate records of 1) study drug r eceived, 2) st udy drug dispensed to the subjects, and 3) drug 
returned by [CONTACT_748]. Subjects will be instructed to return all used and unused study drug to 
the site. All used and unused study drug w ill be retained at the site according to instructions 
provided by [CONTACT_630501]. The study monitor w ill 
review study drug records and inventory throughout the study. 
5.[ADDRESS_841238] ensure that the 
materials are destroyed in compliance with applicable environmental regulations, institutional 
policy and any special instructions provided by [CONTACT_630502], and, that the destruction was adequately 
documented.   
5.6 Treatment Assignment and Randomization 
Subjects will be ra ndomized to study treatment using an Integrated Web Response System 
(IWRS). Subjects will be stratified initially by [CONTACT_630503]/PD subst udy and then by 
a) prior use of fibrates and b) prior and/or current use of UDCA. Subjects will be ra ndomized to 
the treatment groups shown below: 
x Treatment Group 1 (N=45); EDP-305 1 mg orally for 12 weeks 
x Treatment Group 2 (N=45); EDP-305 2.5 mg orally for 12 weeks 
x Treatment Group 3 (N=15); Pl acebo (PBO) orally for 12 weeks 
A minimum of 10 subjects per treatment group w ill be included in the PK/PD subst udy. The 
randomization code will be produced by [CONTACT_630502] (or designee). The Enanta unblinded 
biostatistician or designee will review and approve the final ra ndomization list. 
During the Screening Period, subjects will be identified by a unique screening number assigned 
by [CONTACT_977]. Subjects who have completed screening assessments and are eligible for 
participation in the study w ill be ra ndomized before the first dose of study drug (Day −1 or 
Day 1) and assigned a unique subject number which will be used to identify the subject 
throughout the study. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841239] udy drug doses at home except when study drug w ill 
be administered in the clinic (ie, at the Days 1 and 3, and Weeks 2, 4, 8 and 12 visits). The 
subject will be instructed to take the st udy drug approximately at the same time every day (ie, 
orally in the morning after fasting overnight for a minimum of 8 hours). If a subject forgets to 
take their study drug at their scheduled time, the dose may be taken later that day following a 
minimum of [ADDRESS_841240]; however, no more than [ADDRESS_841241] udy drug (including empty bottles) to the clinic at 
each st udy visit. Both accountab ility and st udy drug compliance w ill be reviewed at each visit as 
indicated in the SoA ( Appendix 1). The number of tablets will be c ounted and the study 
personnel w ill ask the subjects why any doses were missed, if applicable. Any potential reasons 
for lack of compliance with dosing will be monitored and followed up by [CONTACT_630504].   
For any subject demonstrating continued noncompliance of study drug dosing despi[INVESTIGATOR_630483], the Investigator should contact [CONTACT_630505]. 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page [ADDRESS_841242] abstain from taking any prohibited concomitant 
medication through the end of study.  
Details of prior and concomitant medication use will be recorded in the source documentation 
and the electronic case report form (eCRF) as indicated in the SoA ( Appendix 1 ). 
5.8.1 Co-administration of EDP-305 and Ursodiol (ursodeoxycholic acid, UDCA) 
Drug-drug interaction between EDP-305 and UDCA is not anticipated based on available 
EDP-305 drug-drug interaction (see  Section 1.4.2 ), and on UDCA metabolic profile from the 
literature. In the liver, ursodiol is conjugated with glycine or taurine, then secreted into bile. 
These conjugates of ursodiol are absorbed in the small intestine by [CONTACT_630506]. The conjugates can also be deconjugated in the ileum by [CONTACT_630507], 
leading to the formation of free ursodiol that can be reabsorbed and reconjugated in the liver. 
Nonabsorbed ursodiol passes into the colon where it is mostly 7- dehydroxylated to lithocholic 
acid. Some ursodiol is epi[INVESTIGATOR_630484] (CDCA) via a 7-oxo intermediate. Chenodiol 
also undergoes 7-dehydroxylation to form lithocholic acid. These metabolites are poorly soluble 
and excreted in the feces. A small portion of lithocholic acid is reabsorbed, conjugated in the 
liver with glycine, or taurine and sulfated at the [ADDRESS_841243] in feces ( Axcan Scandipharm Inc., 2007 ).
As UDCA is primarily metabolized through conjugation, EDP-[ADDRESS_841244] for EDP-
305 metabolism, as is also supported by [CONTACT_630508][INVESTIGATOR_193310] ( refer to the Investigator’s 
Brochure for additional detail). As reported in the literature, UDCA did not have an effect on midazolam pharmacokinetics (a sensitive CYP3A4 substrate) (
Becquemont et al., 2006 ;Dilger, 
Denk, Heeg, & Beuers, 2005 ).  
UDCA had limited effect on digoxin (a sensitive P -gp
substrate) ( Becquemont et al., 2006 ). Based on this information, UDCA is not expected to have an 
effect on EDP-305 pharmacokinetics during co-administration.  
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page [ADDRESS_841245] three months prior to Screening are allowed. 
However, no dose modification during the study w ill be allowed.  
5.10
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 50 of 87  6. BLINDING  
The study w ill be double-blinded meaning the subjects, Investigators, and site staff w ill be 
blinded to treatment assignment until the completion of the study. 
All study personnel w ill be blinded to treatment assignment except for the following individua ls :  
x Unblinded Enanta/CRO statistician for purpose of generating and monitoring the 
randomization list 
x Unblinded Drug Supply Chain personnel for the purpose of monitoring drug supplies 
x Enanta/CRO Pharmacovigilance Group and Regulatory Affairs representatives when required to satisfy regulatory reporting requirements 
x Bioanalytical Laboratory for the purpose of measuring drug concentrations  
6.[ADDRESS_841246] Results 
Investigators, site personnel and CRO/Sponsor w ill be blinded to the following laboratory tests 
post-Baseline:   
x Biomarker laboratory data  
o FGF19,  
o total bile acids (BA),  
o C4 [7α-OH-4-cholesten-3-one],  
x Fibrosis and inflammatory markers  
o ELF Panel (ie, hyaluronic acid [HA], procollagen III amino terminal peptide 
[PI[INVESTIGATOR_120861]], and tissue inhibitor of metalloproteinase 1 [TIMP-1]) 
o PRO C3 
o Fibrinogen, CRP, alpha2 macroglobulin and haptoglobin 
o Tumor necrosis factor alpha and beta (TNF- α and β) 
o Interleukin (IL)-6,  IL1β 
o AST to Platelet Ratio Index (APRI) 
o Fibrosis 4 (FIB-4) Index 
x Liver Tests  
o ALP 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page [ADDRESS_841247]'s study treatment is 
necessary for clinical management. In such cases, the Investigator must first attempt to contact 
[CONTACT_630509]. In situations in which 
the Investigator has attempted and failed to contact [CONTACT_1689], and/or the urgency of 
the case required immediate action, he/she should use his/her best judgment, based on the nature 
and urgency of the clinical situation, and proceed with unblinding. 
Once a subject's treatment assignment has been unblinded for a medical emergency or urgent 
clinical situation, the Medical Monitor and study coordinator should be notified within 24 hours 
of unblinding of the treatment. Information relating to unblinding (the reason, date, etc.) should 
be clearly recorded in the subject’s study file . In addition, the Investigator should consider 
whether the clinical event that prompted unblinding should be considered a serious adverse event 
(SAE), according to the regulatory definitions or criteria for SAEs, and if so, submit an SAE 
report as described in Section 9.2.
CRO pharmacovigilance will also unblind any SAE reports in compliance with Regulatory 
reporting requirements. In addition, Enanta may unblind individual subjects at any time for 
matters relating to safety concerns. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841248] AND VISIT SCHEDULE  
7.1 Study Visits  
Details of assessments at each visit are presented in the SoA ( Appendix 1).  
7.1.[ADDRESS_841249] 
(IRB) or Ethics Committee (EC) approved ICF and provides authorization to use protected 
health information (See Section 12.1.3) . The ICF will be completed prior to c onduct of any 
study-specific procedures.  
Screening procedures will be conducted as listed in the SoA ( Appendix 1 ). Screening will occur 
over a period lasting no more than [ADDRESS_841250] 
dose of study drug at the Day 1 visit. If any Screening assessment falls outside of that window, 
the Investigator should consult with the Sponsor’s Medical Monitor  to determine if the 
assessment needs to be repeated.   
If a subject does not qualify for study entry due to an out-of-range lab value that is not consistent 
with the subject’s medical history or appears spurious, with the approval of the Medical Monitor, 
the subject may retest that lab parameter once if the Investigator believes that he/she would 
qualify upon retest. 
At the completion of Screening procedures/assessments, subjects who qualify for the study 
should be given detailed instructions on fasting requirements prior to the first dose and when to 
return to the clinic for the Day 1 visit. 
7.1.2 Rescreening 
Subjects who met all eligibility criteria that were current at the time of their Screening Visit may 
be re screened under the following circumstances and with the approval of the medical monitor: 
x Subjects within the Screening Period who met all eligibility criteria, but are not able to 
obtain required documentation within the allotted window for the Screening Period.  
x Subjects who are eligible, but transiently (for personal reasons) unable to commit to all 
study procedures  
7.1.3 Baseline V isit (Day1) 
Subjects who meet all inclusion criteria and none of the exclusion criteria w ill report to the clinic 
on the morning of Study Day 1 after fasting overnight for a minimum of 8 hours. After a review 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 53 of 87  of applicable inclusion/exclusion criteria, subjects who continue to satisfy eligibility 
requirements will be ra ndomized in a 3:3:1 ratio to their treatment group. Predose assessments 
and procedures will be c onducted as noted in the SoA ( Appendix 1 ) and considered Baseline 
values.  
After predose/Baseline study procedures are completed, subjects w ill receive the first dose of 
study drug in the clinic on Day 1 followed by [CONTACT_630510]. Additional PK, 
C4, FGF19 and Bile Acid samples will be collected from subjects at a subset of sites  (PK/PD 
Substudy) that have the technical capab ility to collect and process intensive (l onger duration) 
sampling. PK and PD samples will be collected as described in Section 8.4. 
Before leaving the clinic, subjects will r eceive st udy medication and instructions on how to take 
the medication at home.   
7.1.4 Treatment Period Visits (Day 3, Weeks 2, 4, 8 and 12 /EOT) 
Except for days when there is a clinic visit, subjects will take their daily dose of st udy drug at 
home for 12 weeks. Throughout the 12-week treatment period, subjects w ill return to the clinic 
as shown in the SoA ( Appendix 1) for study assessments.  Prior to each visit, subjects will be 
instructed to fast for a minimum of 8 hrs prior to the scheduled visit time. 
At the end of the treatment period, subjects will complete the EOT visit. Subjects who complete 
12 weeks of treatment will complete the EOT assessments at the Day 84 visit /Week 12. Subjects 
who discontinue treatment early should complete EOT assessments at the time of discontinuation 
(if in the clinic) or as soon thereafter as possible if the subject discontinues treatment while not in 
the clinic. Procedures performed are specified in the SoA ( Appendix 1). 
Population PK and PK/PD samples w ill be collected as specified in the SoA ( Appendix 1) and as 
described in Section  8.4.  
Subjects should discontinue drug on Day 84. Subjects, who return for their EOT Visit after Day 
84, should stop dosing on Day 84 (Week 12 Visit).   
7.1.5 Safety Follow-up Period (End of Study Visit) 
All subjects, including those who discontinue treatment early, should return to the clinic for the 
End of Study (EOS) visit [ADDRESS_841251] dose of study drug for safety assessments 
(Appendix 1). For subjects who complete the study, the EOS visit would be scheduled on Day 
112. Following completion of study procedures, subjects w ill be terminated from the st udy.   
Any subject with ongoing AEs/SAEs (serious adverse events) at the EOS visit should be 
followed until resolution of their AE/SAE or until the Investigator has determined that the event 
has stabilized as discussed in  Section 9.3 . 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841252] Withdrawal / Early Termination 
Subjects are free to withdraw their participation at any time during this clinical trial. The 
Investigator has the right to remove any subject from treatment with study drug or participation 
in the study. However, the Investigator should consult with the Sponsor’s Medical Monitor 
before prematurely removing a subject. For any subject who decides to withdraw from the study, 
the Investigator should inquire about the reason for withdrawal, request that the subject to return 
all unused investigational product(s), request that the subject return for a final visit, if applicable, 
and follow-up with the subject regarding any unresolved adverse events. Although a subject may 
discontinue study treatment, every effort must be made to continue the subject on the study, 
returning for the EOT visit (if prematurely discontinuing treatment) and the safety follow-up 
visit.  
If a subject withdraws from the study and also withdraws consent for disclosure of future 
information, no further evaluations should be performed and no additional data should be 
collected. Enanta may retain and continue to use any data collected before such withdrawal of 
consent. 
For safety monitoring purposes, subjects who withdraw after receiving st udy drug should return 
to the clinic as soon as possible and undergo the EOT evaluations (SoA , Appendix 1). Subjects 
should then return for the Safety Follow Up assessments [ADDRESS_841253] who withdraws with ongoing AEs/SAEs should be followed until resolution of 
their AE(s) or until the Investigator has determined that the AE(s) has stabilized.  
Site personnel w ill attempt to contact [CONTACT_630511]’s preferred method of communication, followed by a 
certified letter if the three attempts were unsuccessful. Any subject who still ca nnot be reached 
following those attempts will be considered Lost to Follow -up. These subjects will be included 
in the analysis as indicated in Section 11.[ADDRESS_841254]’s participation must be 
the health and welfare of the subject. Reasons for withdrawal may include, but are not limited, to 
the following: 
x Adverse Event 
x Noncompliance with study drug dosing or study procedures 
x Lack of efficacy 
x Lost to follow-up 
x Withdrawal by [CONTACT_1130] 
x Protocol deviation  
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 55 of 87  x Pregnancy 
x Sponsor’s decision to terminate the study  
x Other 
Subject-specific stoppi[INVESTIGATOR_630485]/or laboratory abnormalities are outlined in 
Section  10.1. 
Subjects who prematurely withdraw from the study for any reason after having been randomized 
will not be repl aced.  
7.2.2 Documentation of Withdrawal of Subjects  
The reason for early withdrawal/termination/lost-to-follow-up of any subject from the study must 
be documented on the appropriate eCRF. If the reason for early withdrawal is an AE or an 
abnormal laboratory value, the specific event or test result, if available, should be recorded on 
the AE eCRF and the subject should be monitored until the event is resolved or deemed stable by 
[CONTACT_737]. 
7.3 Site or Study Discontinuation 
7.3.1 Study Discontinuation 
The Sponsor has the right to terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following: 
x The incidence or severity of AEs in this or other studies indicates a potential health 
hazard to subjects. 
x Subject enrollment is unsatisfactory. 
x A decision from the IRB/EC or regulatory authority to terminate the st udy. 
If the study is suspended or terminated for safety reasons, Enanta Pharm aceuticals, Inc. w ill 
promptly notify the Investigator and will also inform the regulatory authorities of the suspension 
or termination of the study and the reasons for the action. The Investigator is responsible for 
promptly informing the IRB/EC, and providing the reasons for the suspension or termination of 
the study. 
7.3.2 Site Termination 
A single site may warrant termination under the following conditions: 
x Failure of the site to enroll subjects into the study at an acceptable rate. 
x Failure of the site to comply with pertinent governmental regulations as appropriate. 
x Submission of knowingly false information from the research fac ility to the S ponsor, 
clinical monitor, or governmental authority. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841255] be conducted by [CONTACT_630512]/or site personnel: 
x Return of all study data to Enanta Pharmaceuticals, Inc. or designee. 
x Respond to and complete all requests for data clarifications. 
x Accountab ility and final disposition of used and unused study drug. 
x Review of site records for completeness. 
x Shipment of all applicable biological samples (including PK samples) to the designated 
laboratory. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 57 of 87  8. STUDY PROCEDURES/EVALUATIONS  
All visits and assessments should be conducted as shown in the SoA ( Appendix 1) . 
8.[ADDRESS_841256] 6 months should be recorded. For events 
which occurred more than 6 months ago (and which are not ongoing), only significant or relevant 
events should be entered on the eCRF. Any items in the history that are st ill ongoing should be 
noted as such in the eCRF. All surgeries occurring in adulthood should be recorded in the eCRF while methods of contr aception, if applicable, s hould only be documented in the source 
documents. If possible, the date of diagnosis of PBC should be recorded. 
8.2 Clinical Evaluations 
8.2.1 Vital Sign Measurements and ECGs 
Vital signs will include heart rate (HR), respi[INVESTIGATOR_697], blood pressure (BP) and oral 
temperature. Vital signs will be measured at times shown in the SoA ( Appendix 1 ) after the 
subject has been supi[INVESTIGATOR_2525] [ADDRESS_841257] bedside 12-lead ECG machine that 
calculates heart rate and measures the PR, QRS, QT, RR, and QTc ( QTcF) intervals will be 
utilized. If a bl ood draw and ECG are scheduled at the same time, then the ECG should be 
obtained first.  
The Investigator or designee should review the ECGs in real-time for gross abnormalities and 
interval measurements of concern (absolute readings and for postdose ECGs, change from 
Baseline). Clinical interpretation of the ECGs by [CONTACT_630513] a hard copy of the ECGs.  
The Investigator or designee should repeat any ECG with a change from baseline in QTcF 
>60 msec or a QTcF interval >500 msec. Also, ECGs may be repeated at the discretion of the 
Investigator to account for erroneous readings. 
 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841258] be reviewed to confirm that no clinically significant 
cardiac abnormalities are present.  
8.2.2 Physical Examination 
The Investigator or designee will perform the physical examination. A full physical examination 
will be c onducted at Screening and EOS as indicated in the SoA ( Appendix 1) and will include 
examination of the following systems: head/neck/thyroid; eyes/ears/nose/throat (EENT); 
respi[INVESTIGATOR_696]; cardiovascular; chest, lymph nodes; abdomen; skin; musculoskeletal; and neurological. Breast, anorectal, and genital examinations will be performed when medically 
indicated. All subsequent physical examinations w ill be targeted to new signs and symptoms 
including specific assessments of any changes from previous status. Only clinically significant 
abnormalities should be recorded in the eCRF (eg, use of contact [CONTACT_630514]). 
8.2.3 Weight and Body Mass Index (BMI) 
Height should be recorded once at the Screening visit while weight should be recorded at the 
Screening and EOS visits. BMI should be calculated at the times shown in the SoA ( Appendix 1 ) 
according to the following equation:  BMI=weight (kg)/height (m)
2.   
8.2.4 PBC-40 Quality of Life Assessment 
The PBC-40 Quality of Life Assessment (PBC-40 QoL) is a st udy of health-related quality of 
life (HRQOL). It is a survey containing domains of PBC-40 relate to fatigue, emotional, social, 
and cognitive function, general symptoms, and itch. This measure has been validated for PBC 
and the survey will be provided to sites by [CONTACT_630502]. The PBC-40 QoL will be performed as 
indicated in the SoA ( Appendix 1). 
8.2.[ADDRESS_841259] udy. As listed below, two separate scales w ill be used to 
assess pruritus in subjects.  
x An itch visual analog scale (VAS) will be used to record the intensity of the event ( Furue 
et al., 2013 ). Site personnel should instruct the subject to draw a line on the scale 
corresponding to the maximum intensity of itch.   
x The 5-D itch scale is a multidimensional questionnaire completed by [CONTACT_630515]. The 5D-itch scale includes a range of 0 (no itch) to 10 (worst imaginable itch) 
covering five dimensions: degree, duration, direction, disability and distribution. 
The scales should be completed by [CONTACT_396378] ( Appendix 1). 
 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841260] be recorded in the source documents and eCRF as described below ( Section 9.2 ). At all 
visits, the PI [INVESTIGATOR_630486]. The following are 
examples of open-ended questions that may be used to obtain this information: “How are you 
feeling?” ; "Have you had any medical problems recently?" ; "Have you taken any new medicines 
since your last visit/assessment?"  
It is the Investigator ’s responsibility to ensure any n ecessary additional therapeutic measures and 
follow-up procedures are performed and documented in the subject source notes and eCRF. Any 
medication taken during the course of the study through the end of the study w ill be re corded 
with indication, dosage, route of administration, and start and stop dates of administration. All 
subjects will be questioned a bout concomitant medication at each clinic visit as indicated in the 
SoA ( Appendix 1) . 
8.3 Clinical Laboratory and Diagnostic Procedures 
All laboratory samples will be analyzed by a centralized laboratory. A laboratory reference manual will be provided to the site detailing kit contents, reordering s upplies, sample collection 
(see below), handling, storage and shipment instructions. All unblinded laboratory values w ill be 
reviewed by [CONTACT_737], documented, and the results maintained in the source documents. All out-of-range lab findings require an interpretation as to whether or not they are clinically 
significant. Clinically significant laboratory findings in the opi[INVESTIGATOR_630487] (or SAE as appropriate).   
At all visits blood samples should be collected before the first dose of the study drug. Additional 
clinical laboratory evaluations will be performed at other times if j udged clinically appropriate 
by [CONTACT_737], or if the safety review of the data suggests a more detailed assessment of 
clinical laboratory safety evaluations. Any changes to the scheduled times of the clinical 
laboratory determination will be agreed to by [CONTACT_630516], and documented in the 
study trial master file (TMF). 
For Biomarker analysis, fasting serum or plasma samples should be collected before the daily 
dose of study drug for analysis of FGF19, bile acids, C4, and at visits indicated in the SoA 
(Appendix 1). Samples should be collected after an overnight fast of a minimum of 8 hours. 
8.3.1 Safety Laboratory Assessments 
Blood and urine samples for clinical laboratory assessments w ill be collected according to the 
SoA (refer to Table 14) . Subjects should be instructed to fast for at least 8 hours prior to the 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 60 of 87  blood draw for the laboratory testing for all visits. Samples w ill be collected and processed 
according to the procedures provided by [CONTACT_630517]. 
Creatinine clearance will be calculated using the Cockcroft Gault equation as indicated in the 
Laboratory Manual.     
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 61 of 87  Table 14: Laboratory Evaluations 
CHEMISTRY PANEL 
Alanine Aminotransferase (ALT/SGPT)  
Albumin, Serum  
Albumin/G lobulin (A/G ) Ratio (calculation)  
Alkaline Phosphatase, Serum  
Am ylase  
Aspartate Aminotransferase (AST/SGOT)  
Bilirubin, Total and Direct  
BUN  
BUN/Creatinine Ratio (calculation)  
Calcium, (Serum)  
Creatine Kinase  
Creatinine, Serum (creatinine clearance)  
Uric Acid  
Electrolyte Panel (Na+, K+, Cl-, Bicarb.) 
Phosphorus  
Gamma Glutamyl Transferase (GGT)  
G lobulin, Total  
G lucose, Serum  
Cholesterol, serum  
Lactate Dehydrogenase (LDH)  
Lipas e  
Protein, Total, Serum 
TG (triglycerides)  
Coagulation tests  
INR – PT/PTT  HEMATOLOGY PANEL 
Hemoglobin  
Hematocrit  
Differential WBC Count (percentage and absolute): 
Basophils, Eosinophils, Lymphocytes, Monocytes, 
Neutrophils 
MCH  
MCHC  
MCV  
Platelets  
Red Blood Count  
RBC Morphology 
White Blood Count 
S CREENING TES TS  
Viral serology:  HIV -1, HIV-2, HBV (HBsAg), anti- HCV 
antibodies and HCV RNA 
PBC diagnostic (if needed): AMA/M2/PBC-ANAb 
MARKERS OF CV RISKS AND LIPI[INVESTIGATOR_630488]-CRP  
HDL and LDL -P (high and low-density lipoprotein 
particles using a lipoprotein subfractions test; eg, 
LIPOPROFILE)  
lipoprotein (a) [Lp(a)] assay  
apoA -I, apoB, apoB/A Ratio, apoC3, apoE isoforms (E2, 
E3, E4) Total Cholesterol (TC) 
High Density Lipoprotein – Cholesterol (HDL-C) 
Low-Density-Lipoprotein – Cholesterol (LDL-C) 
TG (triglycerides)  
Total/HDL Cholesterol (CT) Ratio 
Adiponectin  
URINALYS IS   
Routine urinalysis to include: Color and appearance, 
pH, SG, Bilirubin, Glucose, Ketones, Leukocytes, 
Nitrite, Occult blood, Protein, Urob ilinogen, 
Microscopic (including RBCs and WBCs) MARKERS OF FIBROSIS AND INFLAMMATION 
ENHANCED LIVER FIBROSIS (ELF) PANEL  
- Hyaluronic acid (HA),  
- Procollagen III amino terminal peptide ( PI[INVESTIGATOR_120861]) 
- Tissue inhibitor of metalloproteinase 1 (TIMP- 1) 
PRO -C3 
Fibrinogen, CRP, alpha2 macroglobulin and haptoglobin 
Tumor necrosis factor alpha  and beta (TNF- α, β) 
IL-6. IL1β  
AST to Platelet Ratio Index  (APRI)  
Fibrosis 4 (FIB -4) Index  PREGNANCY AND MENOPAUSE TESTS   
Serum pregnancy test  
Follicle-StimulatingHormone (FSH)  
BIOMARKERS 
FG F19 (fasting plasma)  
Total bile acids (fasting serum)  
C4 (7α-OH-4-cholesten-3-one)  
 
8.3.[ADDRESS_841261] dose 
of study drug. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 62 of 87  To confirm childbearing status for women claiming that they are postmenopausal, fo llicle 
stimulating hormone (FSH) will be measured at Screening. Additionally, a serum pregnancy test 
should also be drawn in the event the woman is found to be of childbearing potential based on 
the FSH results. 
8.3.[ADDRESS_841262] been shown to be correlated with the level of 
liver fibrosis assessed by a liver biopsy. These biomarkers include HA, PI[INVESTIGATOR_120861], and TIMP 1. These parameters along with PRO-C3 will be assessed as outlined in Appendix 1.  
Fibrosis will be estimated using the APRI and the fibrosis 4 (FIB -4) formulae. The APRI will be 
calculated by [CONTACT_461377]: 
([AST IU/L / AST ULN] / [Platelet count 10
9/L]) × 100 = APRI 
An online calculator can be found at:  
 https://www.hepa titisc.uw.edu/page/clinical-calculators/apri  
The FIB-4 score will be calculated using the  following formula:  
(Age [years] × AST [IU/L]) / (Platelet count [109/L] × (√ ALT [IU/L]))  
An online calculator can be found at: 
 http://www.hepa titisc.uw.edu/page/clinical-calculators/fib-4  
Refer to the SoA (Appendix 1 ) for the timing of these tests. 
8.3.[ADDRESS_841263] of biomarkers to be collected in this study. 
Fasting serum or plasma samples should be collected before the daily dose of study drug for analysis of FGF19, bile acids, and C4 at visits indicated in the SoA ( Appendix 1 ) at Day 1, and 
Week 2, 4, [ADDRESS_841264] of a minimum of 8 hours. 
For all subjects, samples for FGF19, bile acids, and C4 will be collected predose at the noted 
visits as indicated in the SoA ( Appendix 1).  
PK/PD Substudy (select subjects to consent to participate):  Additional samples will be 
collected from subjects at a subset of sites that have the technical capability to collect and 
process intensive (longer duration) sampling (those also collecting intensive PK) at Day 1 and 
Day 84 (Week 12). Biomarker samples will be collected at predose and 2, 6, and 8 hours 
postdose. Additionally, an ALP sample will be collected at the same time points for subjects 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 63 of 87participating in the PK/PD substudy (ie, predose and at 2, 6, and 8 hours postdose). On scheduled 
visits on Week 2, 4 and 8, samples (FGF19, bile acids, C4 and ALP ) will be collected at three timepoints: predose and at two timepoints postdose; the first samples collected [ADDRESS_841265] 1 hour later. Where possible, the 
samples at each visit s hould be obtained at different times postdose relative to each other. 
8.3.6 Liver Imaging 
To exclude cirrhosis and/or advanced fibrosis, a liver Fibroscan will be c onducted prior to 
Baseline in subjects for whom documented fibrosis stage on a recent liver biopsy (<2 years) 
result is not available and once a subject is considered eligible based on Screening laboratory 
values. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 64 of 87  8.4 Pharmacokinetic Samples 
8.4.1 Collection of Pharmacokinetic Samples 
Plasma samples will be collected and processed to define the PK parameters according to the 
procedures provided and/or approved by [CONTACT_153669], Inc. Plasma PK samples w ill 
be collected as shown in  the SoA ( Appendix 1). More detailed information will be given in the 
Laboratory Manual.   
Population PK( all Subjects):  On scheduled visits at Day 1, and Weeks 2, 4, 8 and 12, PK 
samples will be collected at three timepoints : predose and at two timepoints postdose; the first 
postdose sample collected [ADDRESS_841266] one hour later. Where possible, the samples at each visit s hould be obtained at different 
times postdose relative to each other. 
PK/PD Substudy (select subjects to consent to participate):  Additional samples will be 
collected from subjects at a subset of sites that have the technical capability to collect and 
process intensive (longer duration) PK samples. At Day 1 and Day 84 (Week 12) PK samples 
will be collected at predose and 2, 6, and 8 hours postdose. On scheduled visits on Week 2, 4 and 
8, PK samples will be collected at three timepoints : predose and at two timepoints postdose; the 
first samples collected [ADDRESS_841267] udy Manual. It is important that the date and 
time of collection of each of the PK bl ood samples are accurately recorded in the source 
document. Within 8 hours postdose, an acceptable wi ndow around each PK draw is 
± [ADDRESS_841268] dose taken at home prior to the visit. 
PK samples may be stored and used for future metabolite identification and/or further evaluation 
of the bioanalytica l method. These data will be used for internal exploratory purposes and will 
not be included in the clinical study report. 
8.4.2 Handling and Bioanalysis of Pharmacokinetic Samples  
EDP-305 and its major metabolites (EP-022571, EP-022572, and EP-022679) in human plasma 
will be quantified by [CONTACT_630518] (HPLC) with tandem mass 
spectrometric (LC-MS/MS) detection. The method w ill be fully validated by [CONTACT_630519], accuracy, sensitivity, and specificity of EDP- 305 and its major metabolites by a 
laboratory selected by [CONTACT_153669], Inc.   
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841269] acebo as a control. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 66 of 87  9. SAFETY MONITORING AND REPORTING 
9.1 Definitions 
9.1.1 Pretreatment Events 
A pretreatment event is any event that meets the criteria for an AE/SAE and occurs after the 
subject signs the ICF but before receiving the first administration of st udy drug. 
9.1.[ADDRESS_841270] was enrolled in the study are not to be considered AEs unless the condition 
deteriorated in an unexpected manner during the study (eg, surgery was performed earlier than 
planned). 
9.1.3 Serious Adverse Events (SAEs) 
An SAE is any untoward medical occurrence at any dose that:  
x Results in death: This includes deaths that appear to be completely unrelated to study 
medication (eg, a car accident).  
x Is a life-threatening event: An event that places the subject at immediate risk of death at 
the time of the event; it does not refer to an event that hypothetically might have caused 
death if it were more severe.  
x Requires inpatient hospi[INVESTIGATOR_630489], unless hospi[INVESTIGATOR_062]: 
o routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition 
o elective or pre-planned treatment for a pre-existing condition that is unrelated to the indication under study and has not worsened since signing the ICF 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841271]'s 
general condition 
x Results in permanent or prolonged (at least 28 days in duration) disab ilit y or incapacity.  
x Is a congenital anomaly or birth defect in the offspring of a study subject.  
x Medically important event: An event that may not be immediately life-threatening, or 
result in death or hospi[INVESTIGATOR_059], or require intervention to prevent one of the outcomes 
listed above, but is considered medically significant for other reasons. An opportunistic 
or otherwise unusual infection for the PI's practice, such as tuberculosis, w ill be 
considered medically significant.  
The term severe is used to describe the intensity of a specific event (as in mild, moderate, or 
severe); the event itself, however, may be of minor medical significance (such as severe 
headache). This is not the same as serious, which is based on outcome of the event, as described 
above. Seriousness, not intensity, serves as a guide for defining regulatory reporting obligations. 
9.2 Documenting and Reporting of Adverse Events (Including Serious 
Adverse Events) 
Adverse Events will be evaluated and documented using the grading scales contained in the 
National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) 
(Version 4.03). 
9.2.[ADDRESS_841272]’s source documents. For subjects who do not receive st udy drug (ie, 
screen failures), AEs will only be recorded in the source documents . For subjects enrolled into 
the study (ie, randomized), record all AEs in the subject’s AE  eCRF and Clinical Trials SAE 
Form (if applicable). The AE CRF will indicate if the event occurred prior to the first dose of 
study drug, during treatment, or during the post-dosing follow-up period. Record all AEs 
regardless of the intensity, seriousness, or relationship to study drug.   
Grade AEs (serious and non-serious) in accordance with the NCI/CTCAE scale (available at 
https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf ) as 
presented below:  
x Mild  (Grade 1) asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated 
x Moderate  (Grade 2) minimal, local or noninvasive intervention indicated; limiting age-
appropriate instrumental activities of daily living 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 68 of 87  x Severe  (Grade 3) Severe or medically significant but not immediately life-threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self care 
activities of daily living 
x Life-threatening  (Grade 4) Life-threatening consequences; urgent intervention indicated  
x Death (Grade 5) Death related to the AE. 
Any recurrence of an AE with similar causality to study drug w ill be reported as recurrence or 
exacerbation of the initial event, and not as a new event. Whenever possible, report AEs as a 
specific diagnosis or syndrome (eg, flu syndrome) rather than as individual signs or symptoms. If 
no specific diagnosis or syndrome is identified, AEs should be reported as separate and 
individual events.  
An AE includes the following:  
x Progression or exacerbation of the subject’s underlying disease . Clinical sequelae that 
result from disease progression, such as pleural effusion or small bowel obstruction, are 
reportable as AEs.  
x Pre-existing event that increases in frequency or intensity.  
x Condition detected or diagnosed during the study period, even though it may have been 
present, in retrospect, prior to the first dose of study drug.  
x Laboratory abnormalities outside of normal limits and requiring therapeutic intervention.  
x An overdose of the study drug without any signs or symptoms w ill be considered an AE. 
A calculated dose that exceeds its correct dose by 10% or more and is administered to the 
subject will be considered an overdose and documented as an AE.  
The following events will not  be identified as AEs in this study:  
x Medical or surgical procedures (eg, surgery, endoscopy, tooth extraction, etc); however, 
the condition (the “triggering event”) that leads to the procedure may be an AE.  
x Pre-existing conditions present or detected prior to the first dose of study drug that do not 
worsen. 
9.2.[ADDRESS_841273] attempt to determine the cause of each event. Every effort will be made by 
[CONTACT_153686]. To ensure consistency of 
AE/SAE causality assessments, Investigator(s) should apply the following guideline:  
Related:  There is an association between the event and the administration of study drug, a 
plausible mechanism for the event to be related to the study drug and causes other than the study 
drug have been ruled out, and/or the event re-appeared on re-exposure to the study drug.  
Possibly Related:  There is an association between the event and the administration of the study 
drug and there is a plausible mechanism for the event to be related to study drug, but there may 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841274]’s clinical status or underlying 
disease.  
Unlikely Related:  The event is unlikely to be related to the study drug and likely to be related 
to factors other than study drug.  Not Related:  The event is related to an etiology other than the study drug (the alternative 
etiology must be documented in the study subject’s medical record).  
9.2.3 Classifying Action Taken with Study Drug 
In the case of an AE, the actions that can be taken with study drug are defined below in Table 15 . 
Table 15: Options for Action Taken with Study Drug 
Classification  Definition  
Dose Not Changed  Study drug dose not changed in response to the AE  
Dose Reduced  Study drug dose reduced in response to an AE  
Drug Interrupted  Study drug administration interrupted in response to an AE  
Drug Withdrawn  Study drug administration permanently discontinued in response to an AE  
Not Applicable  Action taken regarding study drug administration does not apply.  “Not applicable” should 
be used in circumstances when no opportunity to decide whether to continue, interrupt or 
withdraw treatment was possible such as when the investigational treatment had been 
completed before the adverse event began.  
9.2.4 Classifying Adverse Event Outcome 
For every AE/SAE, the possible outcomes of the event and the definition of the outcome are 
shown below in Table 16. O ne outcome must be entered into the appropriate field on the AE and 
(if appropriate) SAE form for each event as discussed in the eCRF instructions. 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 70 of 87Table 16:  Classification and Definition of AE Outcomes  
Classification Definition 
Recovered / Resolved Resolution of an AE with no residual signs or symptoms 
Recovered / Res olved with s equelae Resolution of an AE with residual signs or symptoms 
Is Recovering /Is ResolvingIncomplete improvement to date but AE continues to improve/resolve and 
complete resolution is ex pected over time
Not Recovered /N o t  R e so l v e d  Either incomplete improvement or no improvement of an AE, such that it 
remains ongoing 
Fatal Outcome of an AE is death. “Fatal” should be used when death is at least 
possibly related to the adverse event. 
Unknown Outcome of an AE is not known (eg, a subject lost to follow up) 
9.2.[ADDRESS_841275] be reported by [CONTACT_630520], Inc. In addition, all SAEs, including those that result in death, that occur after 
the EOS visit and that are considered related to study drug(s) must be reported to  
 and Enanta within 24 hours of learning of its occurrence. Additional 
details are provided in the Safety Management Plan.  
The electronic SAE Form should be sent to the Study SAE e-mail address to be distributed to all 
recipi[INVESTIGATOR_840]:  
SAEs will be recorded on the Clinical Trials SAE Form using a rec ognized medical term or 
diagnosis that accurately reflects the event. SAEs w ill be assessed by [CONTACT_630521], relationship to the investigational study drug(s) and possible etiologies. On the Clinical 
Trials SAE Form, relationship to study drug(s) w ill be assessed only as related or not related. For
the purposes of study analysis, if the event has not resolved at the end of the study reporting 
period, it will be documented as ongoing. For purposes of regulatory safety monitoring, the 
Investigator is required to follow the event to resolution and report the outcome of the event to 
 using the SAE Form.  
The Investigator is responsible for notifying the Sponsor within 24 hours of identifying an 
SAE, regardless of the presumed relationship to the investigational study drug . The SAE 
Form should be completed for new/initial events as well as to report follow-up information 
on previously reported events . The Investigator is asked to report follow-up information as 
it becomes available .   
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page [ADDRESS_841276] udy sponsor, is responsible for reporting 
suspected, unexpected, serious adverse reactions (S[LOCATION_003]Rs) i nvolving the study drug(s) to all 
regulatory authorities, and participating PIs, in accordance with FDA, ICH Guidelines, and/or 
local regional or country regulatory requirements, as applicable.
9.2.[ADDRESS_841277] dose of study drug/s. 
If a female subject or the female partner of a male subject becomes pregnant while participating 
in the study, study treatment must be permanently discontinued immediately. The Investigator 
must notify the Sponsor’s Medical Monitor  and within one
business day of the sites’ knowledge of the subject’s (or partner’s) pregnancy, by [CONTACT_630522]-specified pregnancy report form. If confirmed to be on active drug, the subject or partner 
will be followed until end of pregnancy and the infant will be followed for one year after the 
birth, provided informed consent is obtained. A separate ICF will be provided to explain these 
follow-up activities. Pregnancy itself does not constitute an AE. 
9.3 Follow-up of Adverse Events and Serious Adverse Events 
Follow all AEs (serious and non-serious) until resolution or otherwise explained (see Table 16 ),
the subject dies, the event stabilizes and is not expected to further resolve with the maximum time limit for stabilization defined as [ADDRESS_841278]. If alternative therapy is instituted, it 
should be documented (see Section 8.2.4 ). Enanta Pharmaceuticals, Inc. may request that the 
Investigator perform or arrange for supplemental measurements or evaluations to further clarify 
the nature of the event. 
9.4 Sponsor’s Review of Adverse Events and Serious Adverse Events
Enanta Pharmaceuticals, Inc. w ill maintain an ongoing review of all AEs and SAEs. 
9.[ADDRESS_841279] (DSMB) 
throughout the study. The DSMB w ill be headed by a DSMB Chair and will include physicians 
with expertise in diseases of the liver including PBC. Procedures for data review including 
timing and potential outcomes will be governed by [CONTACT_304955]. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841280] (see below) and thor ough 
evaluation and follow-up will be performed:  
x If ALT or AST increases to >5 × Baseline. 
x If ALT or AST increase >2 × Baseline AND the increase is accompanied by a 
concomitant TB increase to >2 × Baseline OR the INR concomitantly increases by >0.2 
x If elevations of ALT/AST are accompanied by [CONTACT_630523], anorexia, nausea, vomiting, fever, eosinophilia, and/or rash.  
10.2 Management of Liver Enzyme Elevations 
The FDA Guidance for Industry for Drug Induced Liver Injury (FDA, 2009) w ill provide 
guidance for the management of changes in liver transaminases (ALT/AST) and TB.  
The protocol also includes an algorithm to respond to changes in liver enzymes and functions as 
follow:  
x To establish a baseline utilizing at least [ADDRESS_841281] or ALT elevations 
2 × baseline, subjects will be reassessed promptly (eg, 48-72 hours) with full liver 
biochemistry and physical exam and if the repeat assessment shows persistent elevations 
in transaminases, subjects should be followed according to the “close observation” 
guidelines: 
o Repeat liver enzyme and serum bilirubin tests two or three times weekly. Frequency of repeat testing can decrease to once a week or less if 
abnormalities stab ilize or the trial drug has been discontinued and the subject 
is asymptomatic. 
o Collect additional PK samples at the same visits as safety labs 
o Obtain a more detailed history of symptoms and prior or concurrent diseases. 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 73 of 87oObtain a history of concomitant drug use (including nonprescription 
medications and herbal and dietary supplement preparations), alcohol use, 
recreational drug use, and special diets. 
oRule out acute viral hepatitis types A, B, C, D, and E; autoimmune or 
alcoholic hepatitis; NASH; hypoxic/ischemic hepatopathy; and b iliary tract 
disease. 
oObtain a history of exposure to environmental chemical agents. 
oObtain additional tests to evaluate liver function, as appropriate (eg, INR, direct bilirubin). 
oConsider gastroenterology or hepatology consultations. 
oConsider liver biopsy for any patient with persistent evidence of liver injury. 
xIf a subject lives in a remote area, they can be tested locally with the results promptly 
communicated to the Investigator site .
10.[ADDRESS_841282] be captured on the eCRF as an AE. In addition, as listed below, two separate scales will be 
used to assess pruritus in subjects who report itching.  
xAn itch visual analog scale (VAS) will be used to record the intensity of the event ( Furue 
et al., 2013 ). Site personnel should instruct the subject to draw a line on the scale 
corresponding to the maximum intensity of itch.   
xThe 5-D itch scale is a multidimensional questionnaire completed by [CONTACT_630515]. The 5D-itch scale includes a range of 0 (no itch) to 10 (worst imaginable itch) 
covering five dimensions: degree, duration, direction, disability and distribution. 
If reported, pruritus should be assessed at each visit until resolution of the event. The scales 
should be completed by [CONTACT_423]/site personnel during each assessment/visit where pruritus is 
reported.   
   
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 74 of 87  11. STATISTICAL CONSIDERATIONS 
11.1 General Considerations 
All data will be mapped into the appropriate SDTM domains per version 3.2. All analysis 
datasets will be in the appropriate ADaM data structure . Pi[INVESTIGATOR_11038]21 will be used to ensure 
compliance of the SDTM domains and ADaM datasets to CDISC standards.   
All quantitative endpoints w ill be summarized using an 8-number summary (n, mean, standard 
deviation, median, 25th quartile, 75th quartile, minimum and maximum values). All qualitative 
endpoints w ill be summarized by [CONTACT_630524] e ndpoint and the 
percentage of subjects out of the appropriate population. The denominator w ill be displayed 
when needed.  
Statistical inference will be performed as appropriate . Only two- sided test with an α=0.05 will be 
used.   
11.2 Sample Size Considerations 
 
The planned sample size is approximately 105 subjects. Group sample sizes of 45 in each active 
arm and 15 in the placebo arm achieve 83.552% power to detect a ratio of the group proportions 
of 40%. The proportion in the smallest active arm is assumed to be 0.4000 under the null 
hypothesis and 0.0400 under the alternative hypothesis. The proportion in the placebo arm is 
10%. The test statistic used is the two-sided Mantel-Haenszel test. The significance level of the 
test is 0.05. To account for a 10% discontinuation rate, [ADDRESS_841283] 105 who complete treatment, bringing the total number of subjects enrolled to 
119. 
11.3 Analysis Populations 
The following analysis populations are planned:  
x Safety Population: All subjects who receive at least one dose of st udy medication. 
Subjects will be included in the treatment gr oup that corresponds to the study medication 
received during the st udy. 
x Efficacy Population: All subjects who receive at least one dose of st udy medication. 
Subjects will be included in the ra ndomized treatment group. 
x Pharmacokinetic Population:  All subjects receiving active st udy medication and having 
any measurable plasma concentration of study medication at any timepoint.  
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841284] disposition: 
x Completed study drug per protocol 
x Discontinued study drug early and the reason for discontinuation 
x Completed the study  
x Discontinued from the study early and the reason for discontinuation 
Subject demographics will be summa rized by [CONTACT_630525]. Appropriate baseline characteristics w ill be included in addition to 
demographic characteristics. No statistical testing will be performed. Additional details will be 
provided in the Statistical Analysis Plan. 
11.[ADDRESS_841285] 20% 
reduction in ALP from pre-treatment values or normalization of ALP at Week 12. The denominator will be the number of subjects in the effi cacy population (missing=failure). 
Treatment comparisons will be made using a Mantel-Haenszel test comparing each of the active 
treatment arms to placebo, separately. 
11.5.2  Secondary Efficacy Endpoints 
The secondary effi cacy e ndpoints are as follows: 
x Bilirubin (Total, Conjugated, Unconjugated) decline from Baseline at Week 12 
x Change from Baseline in Alanine aminotransferase (ALT), Aspartate aminotransferase 
(AST), and Gamma-Glutamyl transferase (GGT) at Week 12 
x Change from Baseline of noninvasive liver fibrosis markers (Enhanced Liver Fibrosis 
[ELF] panel, PRO C3, AST to Platelet Ratio Index [APRI] and fibrosis-4 [FIB-4]) at 
Week 12  
x Change from B aseline in fibrinogen, CRP, IL6, IL1 β, TNF -α, TNF -β , alpha2 
macroglobulin and haptoglobin levels at Week 12 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 76 of 87  x Change from Baseline in Triglycerides (TG), Total Cholesterol (TC), High Density 
Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C) at 
Week 12 
x Change from Baseline in 5D-itch scale and Visual Analog Score (VAS) at Week 12 
x Change from Baseline in PBC-40 Quality of Life (QoL) at Week 12 
x Pharmacodynamic parameters of EDP-305: FGF19, C4 and Bile Acid (BA) at week 12 
 
Each endpoint w ill be summarized using an 8-number summary. Subjects in the efficacy 
population w ill be included. Comparisons of treatment arms will be performed using an analysis 
of covariance (ANCOVA) model with treatment and baseline values included in the model 
where appropriate .   
11.6 Safety Endpoints 
11.6.1  Adverse Events 
Adverse events will be summarized by [CONTACT_630526]. All subjects in the safety analysis set will be included in the summaries . No statistical testing will be performed.   
Summaries of Adverse Events will include the following: 
x An overall summary of AEs with a line for each of the categories provided below. 
x Treatment-emergent adverse events 
x Treatment-emergent treatment-related adverse events 
x Treatment-emergent adverse events leading to study drug discontinuation 
x Serious adverse events 
x Serious treatment-related adverse events 
x Adverse events leading to death 
11.6.2  Clinical Laboratory Data 
Summaries of clinical laboratory results will be performed using an 8-number summary by [CONTACT_153690]. All subjects in the safety population w ill be included in these summaries.   
The number and percentage of subjects with treatment-emergent laboratory abnormalities w ill be 
summarized by [CONTACT_1570]. In addition, shift from baseline tables will be generated by [CONTACT_3232]. 
Change from Baseline will be included in summary tables for laboratory parameters. Shift tables 
will also be generated for safety laboratory parameters by [CONTACT_630495]. All 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841286] va lues outside the normal range 
will be flagged. 
11.6.3  Electrocardiogram (ECG) Data 
ECG data will be summarized using an 8-number summary by [CONTACT_29631]. Change from 
Baseline will be included in summary tables for ECG parameters. In addition, the number and 
percentage of subjects with significant changes in ECG parameters will be summarized by 
[CONTACT_3148]. No statistical testing will be performed. 
11.6.4  Vital Signs  
Vital signs data will be summarized using an 8-number summary by [CONTACT_29631]. In 
addition, the number and percentage of subjects with significant changes in vital signs will be 
summarized by [CONTACT_3148]. Change from Baseline will be included in summary tables for vital 
signs. No statistical testing will be performed. 
11.6.5  Concomitant Medications 
The number and percentage of subjects taking concomitant medications will be summarized by 
[CONTACT_630527]. Subjects in the safety population w ill be summarized by [CONTACT_6490]. No statistical testing will be performed. 
11.6.6  Physical Examinations  
Physical examination data will be provided in data listings.  
11.7 Pharmacokinetic Analyses 
The following PK parameters ( Table 17 ) will be calculated as indicated for plasma EDP - 305 and 
its major metabolites as applicable: 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 78 of 87  Table 17: PK Parameters 
PK 
Parameter Description  
AUC last: The area under the plasma concentration-time curve from time zero to the 
time of the last quantifiable concentration.  
Cmax: Maximum observed concentration. 
Tmax: Time to reach C max. If the maximum value occurs at more than one time 
point, T max is defined as the first time point with this value. 
For each EDP- 305 dose level, descriptive statistics (sample size, arithmetic means, geometric 
means, standard deviation, % coefficient of variation, minimum, median, and maximum) will be 
presented. Figures will be created to display mean and individua l subject EDP - 305 concentration 
time curves in plasma on both a linear and logarithmic scale. 
11.8 Interim Analyses 
An interim analysis may be conducted after 25% of the planned total number of subjects have been enrolled and completed 12 weeks of treatment. Additional information will be provided in 
the Statistical Analysis Plan (SAP). 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841287] of the Study 
The study w ill be c onducted in compliance with this protocol, principles of E6 Good Clinical 
Practice: Consolidated Guidance (ICH-GCP), Declaration of Helsinki, and all applicable local 
laws and national regulations governing clinical trials. 
12.1.2  Ethical Review 
It is the PI’s responsibility to ensure that this protocol is reviewed and approved by [CONTACT_153691]/EC which conforms to the regulations set forth in 21CFR, Part [ADDRESS_841288], and all advertisements that may be 
used for study-specific recruitment to the IRB/EC for review and approval before commencing 
study-specific activities. If it is necessary to amend the protocol during the study, then it is the 
responsibility of the Investigator to ensure that IRB/EC approval is obtained before 
implementation of the amended procedures. It is also the responsibility of the Investigator to 
provide the IRB/EC with any SAE or IND safety reports. A copy of the ICF approved by [CONTACT_5040]/EC must be forwarded to Enanta Pharmaceuticals, Inc. for regulatory purposes. 
12.1.[ADDRESS_841289] udy, 
the study procedures, the possible adverse effects, and all other elements of consent as defined in 
§21CFR Part 5, and other applicable national and local regulations governing informed consent. 
Each subject must provide a signed and dated ICF prior to enrollment into this study. Signed 
consent forms must remain in each subject’s st udy file and be available for verification by [CONTACT_33483]. In accordance with individual local and national or c ountry-specific subject 
privacy regulations, the Investigator or designee must explain to each subject prior to Screening 
that for the evaluation of study results, the subject’s protected health information obtained during 
the study may be shared with Enanta Pharm aceuticals, Inc. and its designees, regulatory 
agencies, and IRBs/ECs. As the study sponsor, Enanta Pharm aceuticals, Inc. w ill not use the 
subject’s protected health information or disclose it to a third party without applicable subject authorization. It is the PI ’s or designee’s responsibil ity to obtain written permission to use 
protected health information from each subject. If a subject withdraws permission to use 
protected health information, it is the PI ’s responsibility to obtain the withdrawal request in 
writing from the subject and to ensure that no further data will be collected from the subject. Any 
data collected on the subject prior to withdrawal will be used in the analysis of st udy results.   
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841290] the safety of the subjects, the scope of the 
investigation, or the scientific quality of the study (ie, effi cacy assessments) w ill require 
IRB/IEC notification prior to implementation, except where the modification is necessary to 
eliminate an apparent immediate hazard to human subjects.   
If circumstances require an immediate departure  from protocol procedures, the Investigator will 
contact [CONTACT_630528]. Contact [CONTACT_630529]. Any departures from protocol must be fully 
documented in the source documentation and in a protocol deviation log. 
12.[ADDRESS_841291] w ill be entered into an eCRF by [CONTACT_630530]. It is the 
Investigator’s responsibility to ensure the accuracy, completeness, clarity, and timeliness of the 
data reported in the subject’s  eCRF. Source documentation supporting the eCRF data should 
indicate the subject’s participation in the study and should document the dates and details of 
study procedures, adverse events, other observations, and subject status. The Investigator, or 
designated representative, should complete the eCRF as soon as possible after information is 
collected. An explanation should be provided for all missing data. 
After the subject has completed the study, the Investigator must review and sign the signature 
[CONTACT_630532], to the best of his knowledge, all data recorded in the eCRF accurately 
reflects the subject’s clinical performance in the study.    
Sites are responsible for abiding by [CONTACT_153693]/EC for recording and 
reporting protocol deviations. All deviations reported to the IRB/EC must be reported to Enanta 
Pharmaceuticals, Inc. and/or their designee and recorded as deviations as appropriate in the 
eCRF. 
12.[ADDRESS_841292] udy until 
completion. Monitoring will be c onducted through on-site visits with the Investigator and site 
staff as well as any appropriate communications by [CONTACT_2319], fax, e-mail, or telephone. The purpose 
of monitoring is to ensure compliance with the protocol and the quality and integrity of the data. 
The study monitor w ill insure that the investigation is c onducted according to protocol and 
regulatory requirements, and as described in the Study Monitoring Plan. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 81 of 87  Every effort will be made to maintain the a nonymity and confidentiality of all subjects during 
this clinical study. However, because of the experimental nature of this treatment, the 
Investigator agrees to allow the IRB/EC, representatives of Enanta Pharmaceuticals, Inc., its 
designated agent, and authorized employees of the appropriate regulatory agencies to inspect the 
facilities used in this st udy and, for purposes of verification, allow direct access to the hospi[INVESTIGATOR_630490]. A statement to this effect will be included in 
the ICF authorizing the use of protected health information. 
12.[ADDRESS_841293] access to all source documents, 
eCRFs, and other study documentation for source data check and/or on-site audit inspection.  
12.[ADDRESS_841294] been discontinued or for 2 years following marketing approval of the drug, after 
which time Enanta Pharmaceuticals, Inc. w ill be contact[CONTACT_630531]. Study records w ill contain all of the appropriate documents as detailed in 
Section 8.0 of the E6 Good Clinical Practice: Consolidated Guidance (ICH-GCP).  
12.[ADDRESS_841295] name [CONTACT_54798] (eg, unit discharge 
summary), it must be obliterated before the document is transmitted to Enanta Pharmaceuticals, 
Inc. or its designee. All study findings w ill be stored in electronic databases . As indicated in the 
ICF, subjects will give permission for representatives of the S ponsor, regulatory authorities, and 
the IRB/EC to inspect their medical records to verify the  information collected. Subjects will be informed that all personal information made available for inspection will be handled in the 
strictest confidence and in accordance with local data protection/privacy laws. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_841296]’s personal 
physician or other appropriate medical personnel when required in connection with the subject’s 
continued health and welfare and with the subject’s prior knowledge and permission . 
12.6.[ADDRESS_841297] disclosed.   
All information generated from this study is the proprietary property of Enanta Pharm aceuticals, 
Inc. Enanta Pharmaceuticals, Inc. reserves the right, am ong other things, to: 
x Modify or amend study material to ensure that no confidential or proprietary information 
is disclosed. 
x Ensure that the reported data are factually correct. 
x Utilize the information generated from or as a result of this st udy in any manner it deems 
appropriate, including but not limited to regulatory submissions, annual reports, and other 
scientific or business affairs of the company. 
x Modify the publication or disclosure or delay it a sufficient time to allow Enanta 
Pharmaceuticals, Inc.to seek patent protection of any invention contained therein. 
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 83 of 87  13. REFERENCES 
An, P., Vald, K., Wei, G., Chau, M., Li, Y., Or, Y., . . . Popov, Y. (2017). A novel FXR agonist 
EDP-305 potently suppresses liver injury and fibrosis in mouse models of b iliary and 
metabolic liver disease . Paper presented at the EASL.  
Axcan Scandipharm Inc. (2007). URSO 250 / URSO Forte. Retrieved from 
https://www.a ccessdata.fda.gov/drugsatfda_docs/label/2008/020675s013lbl.pdf  
Becquemont, L., Glaeser, H., Drescher, S., Hitzl, M., Simon, N., Murdter, T. E., . . . Fromm, M. 
F. (2006). Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-
dependent pharmacokinetics in humans. Clin Pharmacol Ther, 79 (5), 449-460. 
doi:10.1016/j.clpt.2006.01.005 
Beuers, U. (2006). Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in 
cholestasis. Nat Clin Pract Gastroenterol Hepatol, 3 (6), 318-328. 
doi:10.1038/ncpgasthep0521 
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015). New paradigms in the treatment of 
hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol, 62 ([ADDRESS_841298]), S25-
37. doi:10.1016/j.jhep.2015.02.023 
Boonstra, K., Beuers, U., & Ponsioen, C. Y. (2012). Epi[INVESTIGATOR_630491]: a systematic review. J Hepatol, 56 (5), 1181-
1188. doi:10.1016/j.jhep.2011.10.025 
Carbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., . . . Jones, 
D. E. (2013). Sex and age are determinants of the clinical phenotype of primary b iliary 
cirrhosis and response to ursodeoxycholic acid. Gastroenterology, 144 (3), 560-569.e567; 
quiz e513-564. doi:10.1053/j.gastro.2012.12.005 
Corpechot, C., Abenavoli, L., Rabahi, N., Chretien, Y., Andreani, T., Johanet, C., . . . Poupon, R. 
(2008). Biochemical response to ursodeoxycholic acid and long-term prognosis in 
primary biliary cirrhosis. Hepatology, 48 (3), 871-877. doi:10.1002/hep.[ZIP_CODE] 
Dilger, K., Denk, A., Heeg, M. H., & Beuers, U. (2005). No relevant effect of ursodeoxycholic 
acid on cytochrome P450 3A metabolism in primary b iliary cirrhosis. Hepatology, 41 (3), 
595-602. doi:10.1002/hep.[ADDRESS_841299] udy of the Liver. (2017). EASL Clinical Practice Guidelines: The 
diagnosis and management of patients with primary b iliary cholangitis. J Hepatol .  
Floreani, A., Caroli, D., Variola, A., Rizzotto, E. R., Antoniazzi, S., Chiaramonte, M., . . . Baldo, 
V. (2011). A 35-year follow-up of a large cohort of patients with primary b iliary cirrhosis 
seen at a single centre. Liver Int, 31 (3), 361-368. doi:10.1111/j.1478-3231.2010.[ZIP_CODE].x 
Furue, M., Ebata, T., Ikoma, A., Takeuchi, S., Kataoka, Y., Takamori, K., . . . Ständer, S. (2013). 
Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement. 
Acta Derm Venereol, 93 (2), 214-215.  
Hirschfield, G. M., & Gershwin, M. E. (2013). The immunobiology and pathophysiology of 
primary biliary cirrhosis. Annu Rev Pathol, 8 , 303-330. doi:10.1146/annurev-pathol-
020712-164014 
Huet, P. M., Vincent, C., Deslaurier, J., Cote, J., Matsutami, S., Boileau, R., & Huet-van 
Kerckvoorde, J. (2008). Portal hypertension and primary b iliary cirrhosis: effect of long-
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 84 of 87  term ursodeoxycholic acid treatment. Gastroenterology, 135 (5), 1552-1560. 
doi:10.1053/j.gastro.2008.07.019 
Ikenaga, N., Liu, S. B., Sverdlov, D. Y., Yoshida, S., Nasser, I., Ke, Q., . . . Popov, Y. (2015). A 
new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, 
early-onset portal hypertension, and liver cancer. Am J Pathol, 185 (2), 325-334. 
doi:10.1016/j.ajpath.2014.10.[ADDRESS_841300], Therneau, T. M., Homburger, H. A., Batts, K. P., . 
. . Dickson, E. R. (2000). Epi[INVESTIGATOR_630492] b iliary cirrhosis in 
a US community. Gastroenterology, 119 (6), 1631-1636. doi:10.1053/gast.2000.[ZIP_CODE] 
Kuiper, E. M., Hansen, B. E., Adang, R. P., van Nieuwkerk, C. M., Timmer, R., Drenth, J. P., . . . 
van Buuren, H. R. (2010). Relatively high risk for hepatocellular carcinoma in patients 
with primary biliary cirrhosis not res ponding to ursodeoxycholic acid. Eur J 
Gastroenterol Hepatol, 22 (12), 1495-1502. doi:10.1097/MEG.0b013e32834059e7 
Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L., Invernizzi, P., Mason, A. 
L., . . . Hansen, B. E. (2014). Levels of alkaline phosphatase and b ilirubin are surrogate 
end points of outcomes of patients with primary biliary cirrhosis: an international follow -up study. Gastroenterology, 147 (6), 1338-1349.e1335; quiz e1315. 
doi:10.1053/j.gastro.2014.08.029 
Lindor, K. D., Gershwin, M. E., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, E. J. 
(2009). Primary b iliary cirrhosis. Hepatology, 50 (1), 291-308. doi:10.1002/hep.[ZIP_CODE] 
Lleo, A., Jepsen, P., Morenghi, E., Carbone, M., Moroni, L., Battezzati, P. M., . . . Invernizzi, P. 
(2016). Evolving Trends in Female to Male Incidence and Male Mortality of Primary 
Biliary Cholangit is. Sci Rep, 6 , [ZIP_CODE]. doi:10.1038/srep25906 
Matsubara, T., Li, F., & Gonzalez, F. (2013). FXR signaling in the enterohepatic system. Mol 
Cell Endocrinol, 38 (1-2), 17-29.  
McMahan, R. H., Wang, X. X., Cheng, L. L., Krisko, T., Smith, M., El Kasmi, K., . . . Rosen, H. 
R. (2013). Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and 
Improves Nonalcoholic Fatty Liver Disease. J Biol Chem, 288 (17), [ZIP_CODE]-[ZIP_CODE].  
Prince, M. I., Chetwynd, A., Craig, W. L., Metcalf, J. V., & James, O. F. (2004). Asymptomatic 
primary biliary cirrhosis: clinical features, pr ognosis, and symptom progression in a large 
population based cohort. Gut, 53 (6), 865-870.  
Selmi, C., Mackay, I. R., & Gershwin, M. E. (2011). The autoimmunity of primary b iliary 
cirrhosis and the clonal selection theory. Immunol Cell Biol, 89 (1), 70-80. 
doi:10.1038/icb.2010.126 
ter Borg, P. C., Schalm, S. W., Hansen, B. E., & van Buuren, H. R. (2006). Prognosis of 
ursodeoxycholic Acid-treated patients with primary b iliary cirrhosis. Results of a 10-yr 
cohort study involving 297 patients. Am J Gastroenterol, 101 (9), 2044-2050. 
doi:10.1111/j.1572-0241.2006.[ZIP_CODE].x 
Trivedi, P. J., Lammers, W. J., van Buuren, H. R., Pares, A., Floreani, A., Janssen, H. L., . . . 
Hirschfield, G. M. (2016). Stratification of hepatocellular carcinoma risk in primary 
biliary cirrhosis: a multicentre international st udy. Gut, 65 (2), 321-329. 
doi:10.1136/gutjnl-2014-308351 
U.S. Food and Drug Administration. (2016). FDA approves Ocaliva for rare, chronic liver 
disease [Press release]. Retrieved from https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm503964.htm  
Clinical Study Protocol 
EDP 305-201 v3.0 (Amendment 2.0, G lobal US and EU) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 85 of 87  Webb, G. J., & Hirschfield, G. M. (2017). Primary b iliary cholangitis in 2016: High-definition 
PBC: biology, models and therapeutic advances. Nat Rev Gastroenterol Hepatol, 14 (2), 
76-78. doi:10.1038/nrgastro.2016.201 
 
 
 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0,G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 86 of 8714. APPENDICES   
Appendix 1: Schedule of Assessments  (SoA) 
Stud y E v ent Scr.1Study Assessments per Planned Study Day EOS
Visit Day (D-28
to -1)D12D3 D14±2 D28±2 D56±2 D843±2 D112±2
Treatment Week4W2 W4 W8 EOT5/W12 W16
ICF6; Demography; Medical History x
Inclusion/Ex clusion x
FSH7; HIV /HCV /HBV x
AMA/M2/PBC-ANAb8x
Pregnancy Test9x x x x x x
Height10, Weight, BMI x x
PT/PTT and INR x x
Oral Temperature x x x
Physical Ex am11x x x x x x x x
V ital Signs12x x x x x x x x
ECG x x x x x
Safety Lab. Tests13x x x x x x x x
PBC-40 QoL x x x x x
V AS and 5-D Itch x x x x x
Biomarkers (FGF19, C4, BA)14x x x x x
CV Markers15x x x x x x
Fibroscan x
ELF panel, PRO-C3, Inflammatory Markers16 x x x
APRI, FIB-4 x x
PK/PD Substudy (PK, C4, FGF19, BA, ALP)17 x x x x x
Population PK Samples18x x x x x
Dispense Study Drug x x x
Study Drug Dosing19daily dosing
Drug Accountability x x x x x
AEs & Con Meds20 x x x x x x x x
                                             
[ADDRESS_841301] udy drug (ie, St udy Days -28 t o -1)
[ADDRESS_841302]-menopausal w omen only 
8 Only if historical values are not available; one test must be positive for study entry to confirm PBC diagnosis (see Inclusion  Criterion #3) 
[ADDRESS_841303] should be obtained as soon as possible to confirm.   
10 Height should only be measured at S creening 
11 Full PE at Screening and EOS; all other exams should be targeted to review of new signs and symptoms 
[ADDRESS_841304] ry (including liver funct ion t est s), hemat ology, and urinalysis and should be collect ed  predose at all 
visits; S ee Tab le 14  for details 
Clinical Study Protocol
EDP 305-201 v3.0 (Amendment 2.0,G lobal US and EU)Enanta Pharmaceuticals, Inc.
CONFIDENTIAL
Page 87 of 87                                                                                                                                                                
14Biomarkers include fasting plasma FGF19, fasting serum bile acids, fasting C4 (7 α-OH-4-cholesten-3-one). Samples should be collected 
aft er a minimum [ADDRESS_841305] udy drug 
15 Lipi[INVESTIGATOR_630493] 14
16Markers of inflammation include fibrinogen, CRP, IL6, IL1 β, TNF -α, TNF -β, alpha2 macroglobulin and haptoglobin (see Tab le 14 ) 
[ADDRESS_841306]  PK/PD samples aft er a minimum [ADDRESS_841307] udy drug.  PK/PD samples on Days 1 and 84 (Wee k 12) 
collected predose and 2, 6, and 8 hr postdose; Weeks 2, 4 and 8 at predose and two samples postdose; the first sample collected [ADDRESS_841308] before the daily dose of study drug. PK samples collected Day  1, Weeks 
2, 4, 8 and 12 at predose and tw o samples postdose; the first sample collected [ADDRESS_841309] is seen in the clinic 
20 Additional samples may be collected to further assess safety events e.g. pruritus 